Susceptibility Contrast Agents for MRI: Physical Basis, Agent Classes, Applications, and Lessons from Clinical Translation

BB

May 2026

This document is a personal technical summary and interpretation of published work. All figures and graphical illustrations in this document were generated using AI-based image-generation tools for the purpose of technical explanation. They do not reproduce or knowingly imitate copyrighted figures from published literature, commercial documentation, or other protected sources. No third-party copyrighted images are used or claimed.

Contents

1 Introduction

1.1 Motivation

Contrast agents in magnetic resonance imaging are often discussed as a single broad class, yet the physical and biological logic of different agent families may be profoundly different. Conventional gadolinium-based contrast agents are small paramagnetic complexes whose most familiar clinical effect is the shortening of the longitudinal relaxation time T_1, thereby increasing signal intensity on appropriately weighted T_1-weighted images. Their distribution is largely governed by vascular delivery and exchange with the extracellular space, so that enhancement commonly reflects perfusion, vascular permeability, and breakdown of physiological barriers [1, 2].

Superparamagnetic iron-oxide agents follow another principle. Rather than acting primarily through local T_1 shortening by isolated paramagnetic ions, they contain magnetic nanoparticle cores with a much larger effective magnetic moment. These particles generate microscopic magnetic-field perturbations in their surroundings, accelerate proton dephasing, and therefore produce strong effects on transverse relaxation, particularly on T_2- and T_2^*-weighted imaging [3, 4]. Their contrast behavior is thus intimately tied to magnetic susceptibility, particle size, magnetic moment, aggregation state, coating, and tissue compartmentalization. This theoretical richness is one reason why susceptibility contrast agents deserve treatment as a separate chapter within MRI contrast-agent science rather than as a minor variant of conventional extracellular contrast media.

The distinction is not purely physical. The biological behavior of superparamagnetic particles is equally characteristic. Depending on their size, coating, and formulation, iron-oxide particles may remain within the vascular space for a useful period, undergo uptake by the reticuloendothelial system, accumulate in macrophage-rich tissues, or serve as labels for cells that are subsequently tracked by MRI [4, 5]. This opens applications that are qualitatively different from standard gadolinium enhancement. SPIOs and USPIOs have been investigated for liver and spleen imaging, lymph-node characterization, vascular inflammation, atherosclerotic plaque imaging, neuroinflammation, brain tumors, cell tracking, and blood-pool or perfusion imaging [4–6].

The term “susceptibility contrast agent” therefore denotes more than a negative contrast medium. It points to a family of agents whose diagnostic meaning arises from the interplay of particle magnetism, relaxometric behavior, biological transport, and pulse-sequence sensitivity. In favorable circumstances, this combination provides access to inflammatory cell recruitment, macrophage activity, or blood-pool physiology in ways that are difficult to reproduce with conventional gadolinium chelates. At the same time, the resulting image contrast may be harder to interpret: signal loss is not intrinsically specific, delayed imaging protocols can be demanding, and biological selectivity does not automatically guarantee straightforward clinical workflow. These strengths and limitations together make the history of SPIOs and USPIOs scientifically instructive.

1.2 Scope of the Report

This report examines susceptibility contrast agents for MRI with primary emphasis on superparamagnetic iron-oxide systems. The discussion centers on SPIOs and USPIOs, but it also includes related and historically important formulations such as monocrystalline iron-oxide nanoparticles, ferumoxides, ferucarbotran, ferumoxtran-10, and ferumoxytol. These agents differ in hydrodynamic size, surface chemistry, circulation

time, uptake pathways, dominant imaging behavior, and degree of clinical development, yet they belong to a common conceptual family of magnetically active particulate contrast media [5, 6].

The report proceeds from physical foundations to practical interpretation. It first summarizes the magnetic and relaxometric basis of susceptibility contrast, including superparamagnetism, local field perturbation, and the principal determinants of T_2 and T_2^* effects. Because this theoretical material is essential for understanding the field but can become technically demanding, a compact account is retained in the main text, while a more detailed treatment is reserved for an annex. Subsequent sections address classes of agents, pharmacokinetics, biodistribution, cellular handling, and the MRI appearance of iron-oxide particles under different imaging conditions.

A substantial part of the report is devoted to applications. These include reticuloendothelial imaging of liver and spleen, lymph-node imaging, macrophage-sensitive vascular and plaque imaging, central nervous system inflammation, ischemic and inflammatory brain lesions, tumor imaging, cellular MRI, and blood-pool or perfusion-based methods. The aim is not merely to list application areas, but to connect each of them to the specific physical and biological properties that made the corresponding imaging strategy plausible [4–6].

Finally, the report deliberately adopts a reflective perspective on translation. Susceptibility contrast agents produced many elegant experimental and early clinical results, yet they did not become a dominant routine contrast-agent platform in MRI. Later sections will therefore examine both sides of this history: what worked scientifically, where the most convincing applications emerged, what practical and interpretive obstacles remained, and why some formulations faded from clinical use while others, especially ferumoxytol, continued to attract attention [6, 7]. The conceptual organization of the report is summarized in Figure 1, which links agent classes, magnetic mechanisms, biological fate, imaging strategies, and application domains.



Figure 1: Conceptual overview of susceptibility contrast agents for MRI, linking particle class, magnetic effect, biological fate, imaging mechanism, and application domains.

2 Physical Basis of Susceptibility Contrast Agents

2.1 Magnetic Susceptibility and Local Field Perturbations

In the MRI context, magnetic susceptibility describes how strongly a material becomes magnetized in response to an externally applied magnetic field. A susceptibility contrast agent is therefore not simply a substance that changes relaxation times by local molecular interaction; it is a material whose magnetization perturbs the surrounding magnetic field. Superparamagnetic iron-oxide particles are especially effective in this respect because their magnetic moments are large compared with those of conventional paramagnetic contrast agents [3, 8].

When an iron-oxide particle is placed in the static field B_0, the particle becomes magnetized and gives rise to a spatially varying secondary magnetic field in its surroundings. Water protons located at different positions near the particle therefore experience slightly different local magnetic fields and precess at slightly different Larmor frequencies. Their phases diverge over time, which accelerates the decay of coherent transverse magnetization. This is the basic physical origin of susceptibility-induced signal attenuation in gradient-echo and, to a lesser extent, spin-echo imaging [3, 9].

The signal effect is often described as a form of microscopic field inhomogeneity. In a perfectly homogeneous field, transverse magnetization remains phase coherent apart from intrinsic relaxation processes. In the neighborhood of a magnetized particle, however, the field is no longer homogeneous on the microscopic scale. Diffusing water molecules continuously sample these local variations, and this fluctuating field exposure contributes to transverse relaxation. The consequences are most conspicuous in

T_2^*-weighted sequences, which are directly sensitive to static and slowly varying field inhomogeneities, but transverse T_2 shortening may also be substantial when diffusion through the perturbed field causes irreversible dephasing [3, 9].

Figure 2 illustrates this chain of causation in a deliberately simplified way: a magnetized iron-oxide particle distorts the local field, nearby water protons accumulate different phases, and the voxel signal decays more rapidly. This picture is conceptually central. The imaging effect is not generated solely "at" the particle surface; it extends into the surrounding water compartment through the magnetic field perturbation created by the particle.

2.2 Superparamagnetism

The term *superparamagnetic* refers to a magnetic state that emerges when a sufficiently small ferrimagnetic or ferromagnetic particle behaves as a single magnetic domain whose net moment can thermally fluctuate in orientation. For iron-oxide nanoparticles, this regime becomes relevant when the particle is small enough that formation of internal magnetic domains is energetically unfavorable. The entire particle then acts approximately as one magnetic moment rather than as a collection of separate domains [3, 10].

In the absence of an external magnetic field, the magnetic moment of such a particle may fluctuate rapidly among energetically equivalent directions. As a result, there is no stable remanent magnetization on the experimental timescale. When an external magnetic field is applied, however, the moments tend to align with that field and the particles can develop a strong magnetization. This combination is highly attractive for contrast-agent design: the particles respond strongly during MRI, yet they do not retain substantial permanent magnetization after the field is removed, which reduces the tendency toward field-independent magnetic aggregation [3, 10].

Two properties are particularly relevant for MRI contrast behavior. The first is the *saturation magnetization*, which describes the maximum magnetization attainable when the particle moments are strongly aligned by the field. The second is the size-dependent stability of the magnetic moment. If particles are too small, their magnetization may fluctuate rapidly and their magnetic moment may be reduced in practice; if they become too large, behavior may depart from the ideal superparamagnetic regime. Contrast-agent design therefore involves a balance between obtaining a large magnetic moment and retaining favorable nanoparticle properties [3, 10, 11].

The distinction between superparamagnetic iron-oxide particles and small paramagnetic molecules is important. A gadolinium chelate carries a magnetic moment on the scale of an individual ion, whereas a superparamagnetic nanoparticle behaves as a magnetically coherent object containing many iron atoms. The resulting magnetic moment per particle is much larger, which explains why comparatively small concentrations of iron-oxide nanoparticles can create pronounced susceptibility-driven MR signal effects [3, 4].

2.3 Relaxation Effects

The dominant MRI effect of SPIOs and USPIOs is usually transverse relaxation enhancement. By creating strong local field gradients, they accelerate the loss of transverse phase coherence and therefore shorten both T_2 and T_2^*. In practice, this often appears as signal loss on T_2-weighted and especially T_2^*-weighted images. The effect may be very strong because a single particle can influence a water volume extending beyond its physical boundaries through the local field disturbance surrounding it [3, 4, 9].

The exact transverse relaxation behavior depends on the relation between particle size, particle magnetization, water diffusion, and the spatial scale of the local field perturbation. Theoretical descriptions commonly distinguish between regimes in which diffusion efficiently averages local field variations and regimes in which protons experience quasi-static magnetic inhomogeneity during the relevant observation time. These ideas underlie later discussions of the motional averaging and static dephasing regimes, which are treated more systematically in the annex [3, 11].

Although iron-oxide particles are often described as negative T_2/T_2^* agents, this characterization is incomplete. Some USPIOs, especially when freely dispersed and under suitable imaging conditions, also possess appreciable longitudinal relaxivity and can generate positive T_1-weighted enhancement. Simon et al. showed that ferumoxtran-10 exhibited measurable T_1 and T_2 relaxivities at both 1.5 T and 3 T, and that the relaxivity changed markedly when the particles were compartmentalized within monocytes rather than freely dispersed in solution [12]. Thus, the imaging behavior of a susceptibility agent cannot be inferred from chemical identity alone; the compartment in which the particles reside is part of the contrast mechanism.

This point is especially important for distinguishing intravascular, extracellular, and intracellular contrast behavior. In the intravascular compartment, long-circulating USPIOs may behave as blood-pool agents and generate susceptibility effects tied to vascular occupancy. When particles reside in extracellular or interstitial space, the relationship between particle concentration and local field perturbation depends on their distribution and degree of clustering. After cellular uptake, particles may become concentrated within intracellular vesicles, changing the spatial arrangement of magnetic material and thereby altering both T_1 and T_2 relaxivity. In the ferumoxtran-10 study by Simon et al., intracellular compartmentalization reduced both longitudinal and transverse relaxivity relative to freely dispersed particles under the experimental conditions investigated [12]. This provides a concrete example of why the physical theory of susceptibility agents must be linked to their biological microenvironment.

2.4 Key Determinants of Contrast Efficiency

Several interdependent factors determine how efficiently SPIOs and USPIOs alter the MR signal. The first is the size of the magnetic core. Larger magnetic cores generally produce stronger local field perturbations because they carry a larger magnetic moment, but the relationship is not unlimited or monotonic in every regime. Theoretical and experimental work by Vuong et al. showed that transverse relaxivity can be described in terms of particle size and magnetization, with an optimum size range predicted for specific classes of magnetic particles [11]. The implication is straightforward but important: maximizing particle size alone is not a sound design principle; the relevant variable is the combination of size, magnetization, and the corresponding relaxation regime.

A second determinant is the hydrodynamic size and surface coating. The coating influences colloidal stability, water accessibility, biological recognition, and effective distance between water protons and the magnetic core. Hydrodynamic size also affects circulation time, tissue access, and uptake by the reticuloendothelial system, although those pharmacokinetic consequences will be treated separately later in the report. From a strictly physical viewpoint, coating and particle architecture alter the geometric relationship between the magnetic source and the diffusing water protons that generate the detectable MR signal [3, 10].

A third determinant is aggregation or clustering. Multiple magnetic cores assembled into larger

structures may create stronger local susceptibility perturbations than isolated cores, but the effect depends on cluster density and geometry. Vuong et al. explicitly incorporated the magnetic volume fraction within aggregates as an additional control parameter for predicting transverse relaxivity of clustered or hybrid nanoparticle systems [11]. Clustering is therefore not merely a nuisance variable; it is a central physical design parameter. At the same time, uncontrolled aggregation may reduce interpretability, change biodistribution, and complicate any attempt to infer particle concentration from signal behavior.

A fourth determinant is the magnetic moment itself, which depends on the material composition and saturation magnetization. Since the local magnetic field disturbance is generated by the magnetization of the particle, a higher magnetic moment can produce stronger susceptibility contrast. Cantillon-Murphy et al. demonstrated experimentally that MRI-based field mapping at 3 T can be used to estimate the magnetization of contrast agents, thereby linking measurable susceptibility effects directly to the underlying magnetic properties of the agent [8]. This illustrates that magnetic characterization is not a remote materials-science concern, but part of the quantitative foundation of contrast-agent behavior in MRI.

Finally, the observed contrast depends on field strength and pulse-sequence design. Gradient-echo methods are especially sensitive to susceptibility-induced field inhomogeneity, whereas spin-echo methods partially refocus reversible dephasing and therefore respond differently. Field strength can also modify the relative visibility of T_1, T_2, and T_2^* effects. The intracellular-versus-extracellular relaxivity measurements of Simon et al. showed that field strength influenced the magnitude of longitudinal relaxivity differences between free and compartmentalized USPIOs [12]. The general lesson is that susceptibility contrast cannot be characterized independently of the sequence and field context in which it is observed.

Figure 3 summarizes these dependencies graphically. It places particle size, coating, clustering, magnetic moment, field strength, and tissue compartment on equal conceptual footing as determinants of contrast efficiency. This is preferable to any overly narrow interpretation that reduces SPIO or USPIO performance to a single variable such as particle diameter alone.



Figure 2: Schematic of a superparamagnetic iron-oxide nanoparticle producing a local magnetic-field perturbation and accelerating transverse dephasing in nearby water protons.



Figure 3: Principal determinants of SPIO/USPIO relaxivity: particle size, coating, clustering, magnetic moment, field strength, and tissue compartment.

3 Classes of Superparamagnetic and Related Contrast Agents

3.1 SPIOs

The term *SPIO* denotes superparamagnetic iron-oxide particles whose hydrodynamic diameter is typically greater than that of the corresponding ultrasmall formulations. In the classification used in several reviews, conventional SPIOs are generally described as particles larger than approximately 50 nm, whereas USPIOs fall below that threshold [5, 13]. The classification is practical rather than perfectly universal, but it captures an important biological distinction: larger SPIOs are cleared more rapidly from the circulation by the mononuclear phagocyte system and therefore show pronounced uptake in organs rich in reticuloendothelial cells, particularly the liver and spleen.

This behavior made SPIOs especially attractive for hepatic MRI. After intravenous administration, normal liver parenchyma, containing Kupffer cells, takes up the particles and becomes darker on T_2- and T_2^*-weighted images, whereas lesions that lack normal reticuloendothelial uptake may remain relatively hyperintense. In the literature assembled for this report, ferumoxides and ferucarbotran are repeatedly discussed as classical SPIO formulations developed for liver imaging [5, 13]. Ferumoxides, marketed as Feridex or Endorem, and ferucarbotran, marketed as Resovist, represent the historically most important examples of this class.

The defining practical feature of conventional SPIOs is therefore not simply their magnetic composition, but the conjunction of particulate size, rapid blood clearance, and preferential uptake by reticuloendothelial tissues. This combination favored imaging tasks in which local particle accumulation in normal phagocyte-rich tissue creates diagnostic contrast against lesions with reduced or absent uptake. It also explains why SPIOs became central to early clinical applications in liver imaging but were less suited than smaller USPIOs for prolonged vascular imaging or access to more remote inflammatory compartments.

3.2 USPIOs

USPIOs, or ultrasmall superparamagnetic iron oxides, are smaller iron-oxide particles with longer blood residence times than conventional SPIOs. In the reviewed literature, they are commonly described as having hydrodynamic diameters below approximately 50 nm, with frequently used formulations falling into the range of roughly 10–40 nm [5, 13, 14]. Their smaller size and surface properties reduce immediate sequestration by the liver and spleen and permit substantially longer intravascular circulation.

This altered pharmacokinetic behavior gives USPIOs a wider range of possible imaging roles. During the early post-injection phase, they may behave as blood-pool agents. Their persistence in the vascular compartment allows steady-state susceptibility measurements, high-resolution blood-volume mapping, and, in some formulations, angiographic applications [13–15]. At later time points, USPIOs may accumulate in macrophages within inflammatory tissue. This property underlies their study in carotid atherosclerotic plaques, ischemic stroke, central nervous system inflammation, renal inflammation, and tumors with inflammatory cellular components [5, 13].

Ferumoxtran-10 illustrates the canonical macrophage-imaging USPIO concept. It is described in the reviewed literature as a dextran-coated USPIO with a hydrodynamic diameter of roughly 15–30 nm and prolonged blood residence, features that allow access to macrophage populations in tissues not immediately reached by larger SPIOs [5]. Ferumoxytol represents another major USPIO formulation, but with a somewhat different translational history: originally developed and used as an intravenous iron therapy,

it became attractive for MRI because of its long circulation time, intravascular behavior during early imaging, and later uptake by macrophages [6, 13].

The distinction between SPIOs and USPIOs is therefore not merely a matter of size nomenclature. It maps onto different biological and imaging regimes. SPIOs are strongly associated with relatively rapid reticuloendothelial uptake and classical organ-specific negative contrast, whereas USPIOs extend the field toward blood-pool imaging, delayed macrophage-sensitive imaging, and a more versatile range of vascular and inflammatory applications.

3.3 MION and Related Monocrystalline Systems

The term *MION*, standing for monocrystalline iron-oxide nanoparticle, is used in the literature for a family of small iron-oxide agents employed particularly in experimental MRI. Wu et al. note that AMI-227, composed of a small monocrystalline iron-oxide core with dextran coating, was often referred to as MION in this context [14]. MION-like agents became especially important in preclinical studies of cerebral blood volume and microvascular function because their prolonged intravascular presence permits high-resolution steady-state measurements.

In such experiments, the microscopic susceptibility effect of the particles alters transverse relaxation rates in proportion to local vascular occupancy. By comparing pre- and post-contrast R_2 or R_2^* behavior, investigators can estimate regional blood-volume-related contrast without the severe temporal-resolution constraints of first-pass bolus methods. Wu et al. review this approach extensively in animal models and emphasize its use for cerebral blood-volume mapping, functional blood-volume studies, and assessment of microvascular parameters [14]. MION-based approaches therefore represent a bridge between iron-oxide contrast-agent physics and quantitative vascular MRI.

The importance of MION-like agents extends beyond classical blood-volume experiments. In dynamic susceptibility contrast MRI research, MION has also served as a reference material in methodological studies because it remains predominantly intravascular and therefore helps separate true susceptibility effects from confounds related to leakage of conventional extracellular gadolinium agents. Stokes et al. used MION as a reference standard in the validation of leakage-correction approaches for multiecho DSC-MRI [16]. This role is conceptually revealing: MION-like systems are not only contrast agents in their own right, but also tools for understanding and improving MRI methodology.

3.4 Named and Historically Important Agents

Several named formulations recur throughout the literature and are worth distinguishing because they embody different stages and ambitions of iron-oxide contrast-agent development.

Ferumoxides. Ferumoxides, known under trade names such as Feridex and Endorem, belong to the conventional SPIO class. They were developed for MR imaging of the liver and are repeatedly cited as prototypical dextran-coated liver agents [5, 13]. Their imaging logic rests on strong reticuloendothelial uptake and consequent negative T_2/T_2^* contrast in normal liver parenchyma.

Ferucarbotran. Ferucarbotran, marketed as Resovist, is another historically prominent SPIO formulation for liver imaging. The reviewed literature distinguishes it from ferumoxides in formulation and injection properties, while placing both agents within the broader class of clinically developed SPIO liver agents

[5, 13]. Ferucarbotran is also represented in the more application-oriented literature as a particle system capable of contributing to both transverse and, under some conditions, longitudinal signal effects.

Ferumoxtran-10. Ferumoxtran-10, also referred to as Combidex or Sinerem in the literature, is one of the most important USPIO agents in the history of macrophage-sensitive MRI. Its small size and prolonged blood circulation enabled investigations in lymph-node imaging, inflammatory lesions, central nervous system disease, and brain tumors [5, 13]. In the materials reviewed here, ferumoxtran-10 repeatedly serves as the model agent for delayed imaging of phagocytic-cell accumulation in pathologic tissues.

Ferumoxytol. Ferumoxytol is a USPIO formulation that occupies a distinctive position in the field. The cited literature emphasizes its suitability for blood-pool imaging, first-pass angiography, cerebral blood-volume mapping, and selected inflammatory imaging applications [6, 15, 17]. Neuwelt et al. highlight its bolus capability and its interest as an alternative MRI agent in patient groups for whom gadolinium use may be problematic [13]. Later review literature treats ferumoxytol as one of the most clinically consequential iron-oxide agents because it links the classical ideas of USPIO vascular persistence and macrophage-related delayed uptake with a formulation that remained pharmacologically relevant outside MRI [6].

Other related nanoparticle systems. The reviewed literature also mentions a number of related iron-oxide formulations, including NC100150, SHU555C, very small particles optimized for positive contrast, and engineered nanoparticles intended for dual-mode or targeted imaging [5, 14]. These systems illustrate the breadth of the field. The SPIO/USPIO distinction is foundational, but the actual design space is much richer: investigators varied core size, coating, charge, aggregation state, and targeting chemistry in order to optimize vascular, cellular, molecular, or theranostic performance.

3.5 Comparative Summary

The classes of superparamagnetic contrast agents can be compared along several linked dimensions. Particle size influences circulation time and tissue access. Coating modifies colloidal stability, biological recognition, and the tendency toward rapid uptake by the reticuloendothelial system. Circulation time, in turn, determines whether the agent behaves mainly as a short-lived organ-targeting particle, a longer-lasting blood-pool agent, or a delayed macrophage-sensitive probe. Uptake mechanisms range from rapid phagocytosis in liver and spleen to more gradual accumulation in macrophage-rich inflammatory tissue. The principal imaging role follows from this biological behavior: negative parenchymal contrast for liver SPIOs, steady-state vascular susceptibility contrast for MION-like systems, and blood-pool or macrophage-sensitive applications for USPIOs [5, 6, 13, 14].

Clinical status has been more heterogeneous than the underlying physics. Ferumoxides and ferucarbotran exemplify the early clinical translation of SPIO liver agents. Ferumoxtran-10 became a central experimental and clinical-research USPIO for macrophage imaging but did not establish a routine clinical foothold. Ferumoxytol became the most enduring later example because it retained a medical role as an iron-replacement drug while continuing to attract MRI interest for vascular and inflammatory applications [6, 13]. The comparative arrangement of these agent classes and representative formulations is summarized in Figure 4.



Figure 4: Comparative overview of SPIOs, USPIOs, MION-like agents, and selected named formulations, emphasizing particle size, circulation, uptake, and typical imaging roles.

4 Pharmacokinetics, Biodistribution, and Cellular Handling

4.1 Blood-Pool Phase

The pharmacokinetic behavior of susceptibility contrast agents depends strongly on particle size, surface coating, and formulation. Conventional SPIOs are removed comparatively rapidly from the circulation, whereas USPIOs remain intravascular for longer periods and can therefore function as blood-pool agents. This prolonged vascular residence is especially relevant for angiography, perfusion imaging, and blood-volume measurements [6, 14].

In the early phase after intravenous administration, circulating USPIOs create microscopic intravascular susceptibility effects. Because the particles remain largely confined to the vascular compartment during this phase, changes in transverse relaxation can be related to the local vascular volume fraction. In animal studies, this property has been exploited for high-resolution mapping of regional blood-volume distributions and for the analysis of vascular changes during functional activation, disease, or pharmacological manipulation [14]. The same principle also made MION-like agents important in experimental microvascular MRI.

Ferumoxytol illustrates the clinical and translational importance of this blood-pool phase. Its relatively long intravascular half-life and its ability to be administered as a bolus have made it attractive for contrast-enhanced MR angiography and perfusion-related imaging. Li et al. demonstrated first-pass contrast-enhanced MRA in humans using ferumoxytol as a USPIO-based blood-pool agent [15]. Bashir et al. further emphasized that ferumoxytol provides a longer acquisition window than standard extracellular

gadolinium-based agents, allowing repeated or delayed vascular imaging after recirculation and dilution in the blood pool [6].

The intravascular phase is not free of practical limitations. Bashir et al. note that highly concentrated ferumoxytol boluses can produce transient intravascular susceptibility artifacts during dynamic imaging, particularly when the injected bolus has not yet sufficiently diluted within the circulating blood volume [6]. Thus, the same physical property that gives blood-pool iron-oxide agents their diagnostic strength—a pronounced susceptibility effect—can also become a source of artifact if injection protocol and sequence design are not suitably matched.

4.2 Reticuloendothelial Uptake

After circulation, iron-oxide particles are progressively removed from the bloodstream by cells of the mononuclear phagocyte system. The liver and spleen are the most prominent organs in this respect, because both contain abundant phagocytic cells capable of taking up particulate material. Bone marrow and lymphatic tissues are also relevant, particularly for smaller USPIO formulations [4, 6].

For conventional SPIOs, rapid uptake by liver Kupffer cells forms the basis of classical hepatic contrast imaging. Normal liver parenchyma accumulates the particles and becomes hypointense on T_2- or T_2^*-weighted images. Focal lesions with reduced or absent reticuloendothelial uptake remain relatively less affected and therefore stand out from the darkened surrounding liver. Bulte and Kraitchman describe this mechanism as the most important classical application of SPIO contrast agents and relate it directly to the clinical use of ferumoxides for liver lesion detection [4].

USPIOs are taken up more slowly, but they too eventually enter reticuloendothelial tissues. Bashir et al. describe delayed ferumoxytol uptake in the liver, spleen, and lymph nodes and note that this delayed tissue handling differs from its initial blood-pool behavior [6]. The liver and spleen may therefore show marked signal changes at later post-administration time points, whereas during the early phase the same agent behaves predominantly as a vascular contrast medium. This temporal separation between intravascular and reticuloendothelial phases is one of the central pharmacokinetic features that makes ferumoxytol and related USPIO agents so versatile.

Reticuloendothelial uptake is diagnostically useful, but it also complicates the interpretation of delayed imaging. Once iron-oxide particles have left the bloodstream and accumulated in phagocytic tissues, the observed MR signal no longer reflects blood-pool distribution alone. Instead, it reflects the combined effects of organ-specific uptake, intracellular compartmentalization, and subsequent particle degradation. Figure 5 summarizes this temporal progression from early circulation to later tissue handling.

4.3 Inflammatory and Cellular Uptake

A defining feature of USPIO-based MRI is the possibility of visualizing macrophage-associated accumulation in inflammatory tissues. Macrophages and related phagocytic cells internalize iron-oxide nanoparticles, leading to local susceptibility-induced signal changes. This principle has motivated applications in atherosclerotic plaque imaging, inflammatory cardiovascular disease, neuroinflammation, renal inflammation, and tumor microenvironment research [4, 6].

The interpretation of such imaging, however, requires care. Iron-oxide enhancement in an inflammatory lesion does not automatically prove that circulating monocytes were labeled in the bloodstream and then migrated into the lesion. Oude Engberink et al. directly compared two approaches in a rat model

of neuroinflammation: transfusion of ex vivo SPIO-labeled monocytes and intravenous administration of free USPIOs. They found that the two strategies produced different temporal enhancement patterns. SPIO-labeled monocytes showed delayed lesion accumulation, whereas free USPIOs produced earlier and stronger enhancement, suggesting that free USPIO signal did not primarily represent peripherally labeled monocytes migrating into the lesion [18]. The authors therefore concluded that ex vivo SPIO labeling of monocytes provides a more specific tool for assessing monocyte infiltration than the interpretation of lesion enhancement after free USPIO injection alone [18].

This distinction is important for the entire field. There are at least three mechanistically different routes by which iron-oxide-associated signal may appear in diseased tissue:

1. uptake of free particles by macrophages or resident phagocytic cells already present in the lesion;
2. leakage or translocation of particles into damaged tissue compartments, followed by local uptake;
3. migration of cells that were deliberately labeled before administration or transfusion.

These mechanisms need not produce identical temporal behavior or identical biological meaning. Oude Engberink et al. explicitly discuss the possibility that, in tissue with blood–brain barrier damage, intravenously administered USPIOs can enter the brain parenchyma independently of monocyte/macrophage infiltration, for example through passive leakage or transcytosis [18]. Their study is a useful warning against treating all delayed iron-oxide signal as direct evidence of macrophage trafficking.

The broader cellular-imaging literature makes a complementary point. Bulte and Kraitchman describe iron-oxide nanoparticles as valuable labels for cells in MRI, but such experiments require a clear distinction between signal arising from particles retained by viable labeled cells and signal arising from free particles, released particles, or secondary uptake by other phagocytes [4]. Cellular handling is therefore central not only to signal generation, but also to biological interpretation.

4.4 Biodegradation and Iron Handling

Iron-oxide contrast agents do not remain indefinitely in their administered nanoparticulate form. After uptake by macrophages, the coating and magnetic core are processed intracellularly. The subsequent fate of the iron is important both for toxicological interpretation and for understanding the persistence of MR signal after administration.

López-Castro et al. examined the biodegradation of the SPIO formulation P904 after uptake by macrophages and demonstrated a progressive transformation of the synthetic iron-oxide cores into ferritin-associated iron [19]. Using electron microscopy methods designed to distinguish residual SPIO material from endogenous ferritin nanoparticles, they observed that the original P904 particles were still recognizable shortly after administration, that mixed populations of residual SPIOs and ferritin-like particles were present at intermediate time points, and that by 30 days after administration in the investigated mouse spleen samples the transformation into ferritin-characteristic particles appeared complete [19]. Their data support the view that iron derived from degraded SPIO cores can be transferred into a physiological intracellular iron-storage pathway.

This finding is conceptually important. The biological fate of iron-oxide agents is not simply “particle clearance” in the narrow sense, but a transition from administered magnetic nanomaterial to iron that is incorporated into endogenous storage structures. López-Castro et al. explicitly discuss ferritin formation

as a mechanism that may reduce concerns related to persistent free iron released during degradation [19]. Their study does not, by itself, settle all questions of long-term safety or the kinetics of all iron-oxide formulations, but it provides a mechanistic demonstration of physiologically meaningful iron handling after macrophage uptake.

The same biodegradation process matters for longitudinal image interpretation. Delayed signal effects may reflect a mixture of residual intact particles, intracellularly compartmentalized particles, and downstream iron-storage products. Moreover, Bashir et al. note that ferumoxytol undergoes delayed reticuloendothelial uptake and produces tissue-dependent signal changes beyond its initial blood-pool phase [6]. Taken together, these observations imply that closely spaced repeat examinations or delayed follow-up studies must be interpreted in light of ongoing particle redistribution and intracellular processing. This is an inference from the reported time-dependent uptake and degradation behavior, not a universal quantitative rule for every formulation.

Figure 5 summarizes the pharmacokinetic and cellular sequence discussed in this section: an early blood-pool phase, progressive uptake by reticuloendothelial organs, lesion-related macrophage accumulation in selected pathologies, and eventual intracellular degradation with incorporation of iron into physiological handling pathways.



Figure 5: Simplified time course of blood-pool circulation, reticuloendothelial uptake, macrophage accumulation, and biodegradation for iron-oxide susceptibility agents.

5 Imaging Mechanisms and Practical MRI Appearance

5.1 Negative Contrast

The most familiar MRI appearance of SPIOs and USPIOs is signal reduction on T_2- and especially T_2^*-weighted images. The physical basis is the strong microscopic field inhomogeneity created by magnetized iron-oxide particles. Water protons in the neighborhood of these particles accumulate phase differences more rapidly, which accelerates transverse dephasing and leads to a local loss of signal [3, 4, 20]. In practice, regions containing a sufficiently high concentration of iron-oxide material therefore appear dark relative to surrounding tissue.

Gradient-echo imaging is particularly sensitive to this effect because it does not refocus static or slowly varying local field disturbances. For this reason, T_2^*-weighted images often show stronger particle-induced hypointensity than conventional spin-echo T_2-weighted images. This high sensitivity is advantageous when the goal is to detect low particle concentrations, macrophage-rich lesions, or labeled cells. At the same time, it makes the method vulnerable to signal loss from other susceptibility sources that are unrelated to the administered particles [4, 20, 21].

A characteristic practical manifestation is the so-called *blooming* effect. The spatial extent of the signal void may become substantially larger than the true physical extent of the particle-containing region, because the local field perturbation spreads beyond the particles themselves. In cellular MRI, this can improve conspicuity of SPIO-labeled cells, but it may also obscure surrounding anatomy and prevent precise localization. Zhou et al. explicitly describe this problem for gradient-echo detection of SPIO-labeled stem cells in the myocardium: the signal void produced by strongly susceptibility-shifted spins may be much larger than the cell cluster itself [21]. Lin et al. similarly note that blooming artifacts and partial-volume effects complicate localization and quantification of magnetic nanoparticles in conventional negative-contrast imaging [22].

Negative contrast is therefore both powerful and imperfect. Its sensitivity is excellent, but the signal void itself is not chemically or biologically specific. A dark focus indicates pronounced local dephasing, not automatically the presence of a particular iron-oxide formulation. This distinction becomes central when susceptibility agents are used in tissues that already contain blood products, calcification, or strong background field heterogeneity.

5.2 Positive-Contrast and Alternative Readouts

Although iron-oxide particles are conventionally discussed as negative contrast agents, they can produce positive signal enhancement under two different kinds of circumstances. First, at sufficiently low concentrations and in suitably T_1-weighted acquisitions, SPIOs and USPIOs may show appreciable longitudinal relaxivity and therefore increase signal intensity. Chambon et al. demonstrated in vitro and in vivo that low concentrations of superparamagnetic iron oxides can generate positive signal enhancement in T_1-weighted spin-echo imaging, whereas higher concentrations cause the signal to decline as transverse relaxation effects dominate [23]. This effect is not merely a curiosity; it explains why positive enhancement may occasionally appear in perfused organs or blood-pool applications, even for agents usually categorized as negative contrast media.

Second, a wide range of dedicated *positive-contrast* strategies has been developed to visualize the off-resonant spins or local susceptibility gradients surrounding SPIO-containing regions while suppressing

ordinary on-resonant background tissue. These methods do not reverse the underlying particle physics. Rather, they exploit the very local frequency shifts and field gradients that normally produce dark signal voids.

Dahnke et al. describe susceptibility gradient mapping (SGM) as a post-processing strategy that transforms local field-gradient information into positive contrast around SPIO-labeled regions [20]. Their paper also reviews earlier approaches such as the White Marker technique and spectrally selective methods that either excite off-resonant water or suppress on-resonant water to reveal particle-induced frequency shifts [20]. Balchandani et al. developed a self-refocused spatial-spectral pulse for positive-contrast imaging of SPIO-labeled cells, again exploiting off-resonance behavior around magnetic particles [24]. Lin et al. provide a broader review of these positive-contrast approaches, including off-resonance excitation, inversion-recovery with on-resonant water suppression, and related strategies designed to improve detectability of magnetic nanoparticles in tissues with poor negative-contrast background conditions [22].

Positive-contrast techniques can improve the specificity of particle localization, but they introduce their own constraints. Some require dedicated pulse-sequence design, prior knowledge of the expected frequency shift, additional scans for anatomical reference, or careful handling of background field inhomogeneity. In a comparative in vivo study, Liu et al. found that SGM, White Marker, and IRON techniques differed in sensitivity, susceptibility to artifacts, and dependence on sequence-specific parameters; no single method was universally superior under all conditions [25]. In addition, positive-contrast images alone may provide insufficient anatomical information and often need to be interpreted alongside conventional magnitude images [25].

An alternative route is provided by ultrashort-echo or frequency-sensitive methods designed to reduce the loss of rapidly dephasing signal. Zhou et al. investigated SWIFT for detection of SPIO-labeled stem cells in the rat heart. Compared with gradient-echo imaging, SWIFT retained more total signal, reduced blooming-related ambiguity, and provided useful anatomical information in magnitude images while emphasizing off-resonance components in complementary image representations [21]. This illustrates an important principle: practical imaging of iron-oxide agents need not be limited to accepting a conventional dark void; sequence design can be used to recover, redistribute, or reinterpret susceptibility-driven signal behavior.

5.3 Delayed Imaging Versus First-Pass Imaging

The practical meaning of iron-oxide enhancement depends strongly on imaging time after administration. During the early vascular phase, long-circulating USPIOs such as ferumoxytol behave predominantly as blood-pool agents. This makes them useful for first-pass MR angiography, dynamic perfusion imaging, and vascular blood-volume measurements. Li et al. demonstrated first-pass contrast-enhanced MRA in humans with ferumoxytol, while Neuwelt et al. emphasized that its early slow extravasation relative to conventional extracellular gadolinium agents can be advantageous for vascular imaging in tissues with a disrupted blood–brain barrier [13, 15].

In this early phase, the relevant biological question is largely vascular: where is the agent in the blood pool, and how does its susceptibility effect report on vessel filling, vascular volume, or first-pass passage? Neuwelt et al. explicitly distinguish this from later post-administration behavior, noting that ferumoxytol acts as a blood-pool agent at early time points but may provide delayed anatomical enhancement in brain tumors and related lesions at later time points [13]. Bashir et al. likewise describe both angiographic and

delayed tissue-imaging applications of ferumoxytol, highlighting the unusually broad temporal window created by its prolonged intravascular and subsequent reticuloendothelial handling [6].

Delayed imaging addresses a different class of questions. After sufficient time has passed, USPIOs may accumulate in macrophages, inflammatory lesions, tumor-associated phagocytic cells, or reticuloendothelial tissues. In such circumstances, the imaging readout is no longer a simple blood-pool measurement. It reflects tissue transport, particle uptake, local cellular handling, and possibly barrier disruption. Manninger et al. reported altered enhancement patterns with ferumoxtran-10 in several central nervous system inflammatory lesions compared with gadolinium enhancement, underlining that delayed USPIO imaging can reveal biological information different from conventional immediate extracellular contrast behavior [26]. Kooi et al. similarly used delayed USPIO-enhanced MRI to detect macrophage-rich human carotid atherosclerotic plaques, with post-contrast imaging performed after a delay that allowed plaque-associated uptake to occur [27].

The difference between first-pass and delayed imaging is therefore not a minor protocol detail, but a change in the biological interpretation of the signal. First-pass and early equilibrium imaging predominantly exploit vascular occupancy; delayed imaging seeks information about tissue uptake, macrophage involvement, and inflammatory biology. Figure 6 explicitly juxtaposes these modes so that the reader does not conflate vascular susceptibility imaging with later phagocytic-cell-sensitive imaging.

5.4 Confounds and Interpretation Pitfalls

The sensitivity of susceptibility-based imaging is inseparable from its vulnerability to confounding signal sources. Hemorrhage is especially important. Blood degradation products generate strong susceptibility effects and can produce signal loss on T_2^*-weighted imaging that resembles the appearance of iron-oxide particles. Zhou et al. therefore caution that SPIO-induced signal voids in gradient-echo images may be difficult to distinguish from hemorrhage and other intrinsic causes of rapid transverse dephasing [21]. Liu et al. further note that hemorrhage may interfere even with positive-contrast techniques, depending on the method used and the iron content of the affected region [25].

Calcification and tissue–air interfaces present related challenges. Although calcification is often approached differently in diagnostic interpretation than hemorrhage, it can nevertheless contribute to local field perturbation and create ambiguity in susceptibility-sensitive imaging. Zhou et al. explicitly list calcification and tissue–air boundaries among the intrinsic sources of T_2^* shortening that may complicate SPIO detection [21]. Air–tissue interfaces are particularly problematic in phase-sensitive susceptibility methods. Sehgal et al. note that susceptibility-weighted imaging suffers residual artifacts near such interfaces even after phase filtering [28]. Liu et al. likewise show that positive-contrast methods may display or suppress susceptibility artifacts at tissue–air interfaces depending on the technique and gradient direction considered [25].

A further difficulty lies in background susceptibility heterogeneity. Tissues with pre-existing signal voids, strong iron deposition, surgical change, or complex local field structure may reduce the specificity of both negative- and positive-contrast approaches. Lin et al. emphasize that conventional T_2- and T_2^*-weighted imaging can be difficult to interpret in regions with low baseline signal or pronounced intrinsic magnetic inhomogeneity [22]. This concern is especially relevant for applications in the brain, lung-adjacent structures, postoperative lesions, and tissues with blood-product deposition.

Cellular MRI introduces another interpretive problem: persistence of iron signal does not automatically

mean persistence of living labeled cells. Bulte and Kraitchman note that non-genetic particulate labels may eventually be degraded, leave the original cell, or be incorporated into neighboring cells, which limits the biological certainty of long-term cell-tracking experiments [4]. The MRI signal may therefore outlast the originally labeled viable cell population or change its cellular carrier over time. This is particularly important when SPIO labeling is used to infer cell survival, engraftment, or migration. The imaging readout remains highly sensitive to iron-containing material, but the interpretation of that material requires biological caution.

Figure 6 summarizes the main visual and temporal modes discussed in this section: conventional negative contrast, positive-contrast strategies, early blood-pool imaging, and delayed inflammatory or cellular imaging. The figure also helps frame the central practical lesson: susceptibility agents provide powerful contrast, but image appearance must always be interpreted together with sequence choice, imaging time, tissue environment, and competing sources of local magnetic field disturbance.



Figure 6: Comparison of common MRI appearances of susceptibility agents: negative contrast on T_2/T_2^*, occasional positive contrast, first-pass vascular use, and delayed cellular/inflammatory imaging.

6 Major Application Domains

6.1 Liver, Spleen, and Reticuloendothelial Imaging

The earliest clinically important application domain of superparamagnetic iron-oxide agents was imaging of the reticuloendothelial system, especially the liver. This use follows directly from the pharmacokinetics of conventional SPIOs: after intravenous administration, particles are taken up by phagocytic cells of the mononuclear phagocyte system, with particularly strong accumulation in hepatic Kupffer cells. Normal

liver parenchyma therefore shows marked signal reduction on T_2- and T_2^*-weighted images, whereas lesions lacking normal Kupffer-cell content remain relatively less affected. The resulting lesion-to-liver contrast can improve lesion conspicuity and aid characterization.

This contrast mechanism proved particularly useful in the evaluation of malignant hepatic lesions. Vogl et al. compared unenhanced MRI with SPIO-enhanced MRI using ferucarbotran in patients with malignant liver tumors and found that SPIO-enhanced imaging contributed to preoperative lesion assessment when compared with established surgical reference methods [29]. The basic diagnostic principle is straightforward: metastases and many malignant primary liver lesions do not contain a normal reticuloendothelial cell population, and therefore they do not darken to the same degree as surrounding hepatic tissue after SPIO uptake.

The same principle can be diagnostically informative in lesions that retain some reticuloendothelial function. Grazioli et al. examined focal nodular hyperplasia using both gadobenate dimeglumine and SPIO-enhanced MRI and showed that the behavior of such lesions can reflect their preserved reticuloendothelial component [30]. This is an important reminder that SPIO-enhanced liver imaging is not based simply on "tumor versus no tumor," but on tissue-specific particle uptake. Lesions with functioning Kupffer-like cells may behave differently from lesions devoid of such cells.

The spleen and bone marrow also participate in reticuloendothelial iron-oxide uptake, but historically the liver dominated the clinical use of SPIO contrast agents. The significance of this application domain is twofold. First, it established that susceptibility agents could provide clinically useful information by exploiting biological uptake rather than extracellular leakage alone. Second, it demonstrated the broader diagnostic logic that underlies many later USPIO applications: magnetic nanoparticles become informative when their biodistribution differs between normal and pathologic tissue.

6.2 Lymph-Node Imaging

USPIO-enhanced MR lymphography represents one of the most conceptually elegant application areas of iron-oxide MRI. The method exploits physiological nanoparticle uptake by macrophages in normal lymph nodes. After intravenous administration of USPIOs, normally functioning nodal tissue accumulates particles and shows signal reduction on T_2- and T_2^*-weighted images. Metastatic replacement of nodal macrophage-rich tissue diminishes or abolishes this uptake, so affected nodal regions remain relatively hyperintense after contrast administration [31].

Bellin et al. described this principle in their early clinical experience with iron-oxide-enhanced MR lymphography and emphasized its potential to improve the detection of nodal metastases beyond size-based criteria alone [31]. This point is clinically important. Conventional cross-sectional nodal staging often relies heavily on lymph-node size, yet small metastatic nodes and enlarged reactive benign nodes can both lead to diagnostic uncertainty. USPIO-enhanced lymphography instead asks a functional question: does the node still behave like macrophage-containing normal lymphatic tissue?

The method was therefore attractive not only for identifying enlarged abnormal nodes, but also for detecting metastatic involvement in nodes that might still fall within normal size limits. Bellin et al. explicitly note the potential value of USPIO-enhanced MRI for identifying micrometastatic disease in normal-sized nodes [31]. This application domain remains a paradigmatic example of what iron-oxide agents can contribute beyond the capabilities of conventional extracellular gadolinium enhancement: a contrast mechanism tied to cell population and tissue function rather than to vascular permeability alone.

At the same time, the lymph-node application also foreshadows a recurring translational challenge in the field. Biologically sophisticated imaging may provide excellent mechanistic appeal, but broader clinical adoption depends on robustness, standardization, and the practical consequences of false-positive and false-negative interpretations. The later reflective section of this report returns to this issue.

6.3 Atherosclerotic Plaque and Vascular Inflammation Imaging

Atherosclerotic plaque imaging became one of the most influential research applications of USPIO-enhanced MRI. The rationale is biologically compelling: macrophage infiltration is a central feature of inflammatory and potentially vulnerable plaques, and USPIO accumulation within macrophages can alter local MR signal. The aim is therefore not merely to measure luminal stenosis, but to obtain information about inflammatory activity within the vessel wall.

Kooi et al. provided early human evidence that USPIOs accumulate predominantly in macrophage-rich, ruptured, or rupture-prone carotid plaques and that this uptake can produce detectable in vivo signal changes on MRI [27]. Trivedi et al. extended this line of work in symptomatic carotid stenosis, reporting USPIO accumulation in macrophages in a large majority of studied plaques and corresponding signal reductions in the vessel wall on post-contrast imaging [32]. These studies established USPIO-enhanced MRI as a plausible noninvasive method for visualizing plaque inflammation.

The translational appeal of this approach lies in the mismatch between vascular anatomy and plaque biology. A purely angiographic assessment of stenosis does not directly reveal macrophage burden, fibrous-cap integrity, or the inflammatory state of the lesion. Tang et al. therefore investigated inflammatory burden in carotid plaques contralateral to symptomatic stenoses and showed that USPIO-enhanced MRI could reveal signal changes consistent with inflammatory activity even outside the index symptomatic side [33]. The implication is that vascular risk may not be adequately described by stenosis severity alone.

Later work also broadened the application beyond carotid plaque imaging in the strict sense. Smits et al. evaluated ferumoxytol-enhanced MRI for quantification of arterial wall inflammation, demonstrating the continued interest in translating USPIO-based vascular inflammation imaging into a more quantitative framework [34]. These studies together show why plaque imaging became a flagship application of susceptibility nanoparticles: it links a biologically meaningful cellular process, macrophage recruitment, with a measurable MRI effect.

6.4 CNS Inflammation and Neuroinflammation

The central nervous system presents a different but equally important application domain. Gadolinium enhancement indicates abnormal permeability of the blood–brain barrier, but it does not directly report the inflammatory cellular composition of a lesion. Ferumoxtran-10 and related USPIOs were therefore studied as agents that might add information about phagocytic-cell involvement in inflammatory or vascular brain lesions.

In an exploratory clinical study of diverse CNS inflammatory lesions, ferumoxtran-10 showed enhancement patterns that differed from gadolinium enhancement, with stronger or more extensive enhancement in selected cases of vascular and inflammatory pathology [26]. The interpretation advanced in that study was that ferumoxtran-10 may reflect not only barrier abnormality but also the presence of phagocytic cells within or around lesions. This distinction is important: gadolinium enhancement and USPIO enhancement need not coincide because they are sensitive to different biological features.

Multiple sclerosis and related demyelinating lesions were investigated in this context, but the findings were not uniform. The cited ferumoxtran-10 study reported that several MS lesions showed less enhancement with ferumoxtran-10 than with gadolinium, suggesting that high-molecular-weight USPIO access and macrophage-associated retention do not simply mirror conventional contrast enhancement [26]. This complexity is scientifically useful because it demonstrates that USPIO-enhanced neuroimaging is not merely a delayed surrogate for gadolinium imaging.

Stroke-associated inflammation constitutes a second important CNS application. Saleh et al. reported that iron-oxide-enhanced MRI suggested variability of inflammatory activity at early stages after ischemic stroke [35]. Nighoghossian et al. likewise investigated USPIO-enhanced MRI after ischemic stroke in patients and linked the observed findings to inflammatory recruitment after cerebral ischemia [36]. The combined relevance of these studies is that post-ischemic neuroinflammation may become visible through delayed particle-associated signal changes, offering information complementary to diffusion, perfusion, and conventional contrast-enhanced MRI.

These investigations should not be overinterpreted. The presence of USPIO-related signal does not in itself specify a single transport mechanism or prove a unique cellular pathway. Nevertheless, the CNS literature demonstrates that iron-oxide agents can reveal aspects of lesion biology that are not reducible to conventional blood–brain barrier leakage alone.

6.5 Brain Tumors and Tumor-Associated Macrophages

Brain tumors occupy a particularly rich position in the history of iron-oxide MRI because they combine abnormal vasculature, blood–brain barrier disruption, inflammatory reaction, and macrophage or microglial infiltration. These factors make it possible for ferumoxtran-10 and ferumoxytol to generate signal patterns different from those of conventional gadolinium enhancement.

Murillo et al. investigated ferumoxtran-10-enhanced MRI in brain tumors and reported delayed enhancement patterns that could extend beyond gadolinium-enhancing regions in selected lesions [37]. The study emphasizes that ferumoxtran-10 signal should not simply be equated with tumor-cell enhancement. Rather, the observed enhancement pattern was interpreted in relation to barrier disruption and accumulation in reactive inflammatory components of the lesion. The cited material explicitly distinguishes reactive astrocytes and macrophages from tumor cells as likely contributors to the delayed signal behavior discussed in this context [37].

A related line of work examined tumor-associated macrophages more directly. Daldrup-Link et al. used clinically applicable iron-oxide nanoparticles for MRI of tumor-associated macrophages and showed that macrophage-related nanoparticle uptake can be visualized in tumor-bearing models [38]. This connects the clinical ferumoxtran-10 observations with a broader mechanistic idea: iron-oxide contrast may reveal part of the immune and stromal microenvironment of tumors rather than merely the vascular permeability map.

Ferumoxytol added another dimension. Bashir et al. review its use in MRI as both a blood-pool and delayed tissue-enhancement agent, and discuss its potential relevance for brain-tumor imaging and perfusion methods [6]. The distinction between early and delayed imaging is critical here. Early ferumoxytol imaging may emphasize vascular behavior, whereas delayed imaging can reflect retention in regions with barrier abnormality and phagocytic-cell involvement. This duality requires careful interpretation, but it also makes ferumoxytol particularly versatile.

The tumor literature therefore shows that susceptibility agents can interrogate at least three related but distinct features: vascular volume, barrier abnormality, and inflammatory-cell involvement. A central interpretive task is to avoid conflating these mechanisms. The imaging appearance must be read in the context of administration timing, pulse sequence, and the biological question being asked.

6.6 Cellular MRI and Cell Tracking

Cellular MRI emerged as one of the most ambitious uses of SPIO-based contrast. Here the particles are not administered merely to distribute according to tissue pharmacokinetics; instead, cells are intentionally labeled with iron-oxide particles and later followed by MRI after transplantation, infusion, or migration. The attraction of this method is obvious: it promises noninvasive tracking of cellular therapies or immune-cell trafficking in vivo.

Arbab et al. demonstrated efficient magnetic cell labeling using protamine sulfate complexed to ferumoxides, thereby establishing a practical route for introducing iron-oxide particles into cells for MRI tracking [39]. Such methods opened the door to a wide range of experimental applications, including stem-cell studies and immune-cell delivery. Sheu et al. later used MRI to monitor transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma in a preclinical rodent model [40]. This illustrates the conceptual strength of cellular MRI: the image is used to visualize the biodistribution of a therapeutic cellular product rather than of a freely circulating contrast agent alone.

However, cellular labeling is not biologically neutral in every setting. Schäfer et al. reported that clinically approved SPIO particles used for labeling mesenchymal stem cells aggravated clinical symptoms in an experimental autoimmune setting [41]. Such findings are an important corrective to any overly casual notion that iron labeling is merely an inert marker. The labeling protocol, particle formulation, target cell type, and disease model may all influence biological outcome.

A further interpretive caveat concerns the persistence of iron signal. Signal detected at a later time point does not automatically prove that the originally labeled cells remain viable, functional, or even present as the sole carriers of the iron. Iron particles may persist after cell death, be released, or be transferred to phagocytic cells. This limitation is discussed broadly in the cellular MRI literature and is fundamental when interpreting long-term cell-tracking experiments [4]. In other words, MRI can track iron-associated signal with high sensitivity, but the biological identity of that signal requires careful validation.

6.7 Perfusion, Blood Volume, and Vascular Function MRI

USPIOs and MION-like agents became important tools for perfusion, cerebral blood-volume imaging, and functional vascular MRI because of their prolonged intravascular residence. Unlike rapidly extravasating extracellular gadolinium agents in tissues with barrier breakdown, long-circulating iron-oxide blood-pool agents can remain predominantly vascular during the relevant imaging window. This enables methods that focus more directly on vascular volume and vascular response.

Wu et al. reviewed the use of USPIOs in animal models for measurements of blood volume, functional activation, and vascular physiology, emphasizing the methodological value of long-lived intravascular susceptibility agents [14]. Qiu et al. extended this principle to contrast-enhanced functional blood-volume imaging in humans using ferumoxytol and reported enhanced sensitivity for brain activation relative to conventional BOLD approaches [42]. The key idea is that the contrast agent sensitizes the MR signal to

changes in vascular volume, thereby providing a functional readout distinct from standard endogenous susceptibility effects.

Ferumoxytol was also used in tumor perfusion and blood-volume assessment. Gahramanov et al. investigated perfusion MRI in a glioma model and showed that ferumoxytol can be used to assess intracerebral tumor blood volume and treatment-related vascular effects [17]. Varallyay et al. later compared cerebral blood-volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI to standard-of-care approaches, reinforcing the methodological interest in ferumoxytol for vascular tumor imaging [43]. In addition, Li et al. demonstrated first-pass MRA in humans using ferumoxytol as a blood-pool agent, connecting vascular imaging and perfusion imaging within the same broader pharmacokinetic logic [15].

These applications are methodologically important because they show that iron-oxide agents are not confined to delayed macrophage-sensitive imaging. They also support highly time-resolved or steady-state vascular measurements, depending on acquisition design and the contrast agent chosen. In Figure 7, this is represented as a separate application class rather than as a mere technical detail of another domain.

6.8 Cardiovascular and Myocardial Inflammation Imaging

Beyond carotid plaque assessment, USPIO-enhanced MRI has been investigated for inflammatory processes in the myocardium and arterial wall. The general principle remains the same: if macrophage accumulation accompanies disease activity, delayed uptake of USPIOs may provide an MRI-sensitive marker of that inflammatory burden.

Alam et al. studied USPIO uptake in patients with acute myocardial infarction and reported signal changes consistent with accumulation in infarcted tissue and, to a lesser extent, peri-infarct and remote myocardium [44]. Their work was explicitly framed as early clinical experience and a proof of principle that cellular inflammation after myocardial infarction may be accessible to MRI using iron-oxide particles. The study also discussed the need for careful validation of the biological interpretation of the signal, particularly with respect to macrophage recruitment and particle clearance.

Lagan et al. later developed a more elaborate multiparametric, multi-time-point USPIO MRI methodology intended to distinguish passive interstitial distribution from active macrophage uptake in myocardium [45]. In that study, the R_1 time course was interpreted as reflecting passive interstitial behavior, whereas multi-time-point R_2^* and the derived R_2^*/R_1 ratio were used to identify active macrophage-related uptake. The work is important because it explicitly addresses a recurring interpretive problem in susceptibility-agent imaging: delayed signal change may represent more than one mechanism, and a multiparametric strategy may help separate them.

Together with the arterial wall inflammation work of Smits et al. [34], these studies show that cardiovascular USPIO MRI developed beyond carotid plaque proof-of-principle studies toward broader questions of inflammatory remodeling in vascular and myocardial disease. The translational attraction is clear, but so is the methodological challenge: imaging must differentiate blood-pool behavior, passive tissue distribution, and phagocytic-cell-associated uptake if it is to support strong biological claims.

The principal application domains discussed in this section are summarized in Figure 7. The figure links each domain to its dominant biological target and imaging logic: reticuloendothelial uptake in liver and spleen, macrophage-sensitive contrast in plaques and inflammatory lesions, cellular labeling in cell tracking, and blood-pool susceptibility effects in perfusion and vascular MRI.



Figure 7: Matrix of major application domains for SPIO/USPIO agents, linking biological target, dominant imaging mechanism, and representative clinical or preclinical use.

7 Experiences Made: What Worked, What Did Not

7.1 Where the Field Was Scientifically Convincing

The scientific attraction of SPIO and USPIO imaging was never merely fashionable enthusiasm for nanoparticles. It rested on a coherent chain of physical, biological, and imaging arguments. Superparamagnetic iron-oxide particles possess high magnetic susceptibility, produce strong transverse relaxation effects, and can be engineered to exhibit distinct pharmacokinetic behavior according to particle size and coating. Larger SPIOs rapidly enter reticuloendothelial organs, whereas smaller USPIOs circulate longer, can act as blood-pool agents, and may later accumulate in macrophage-rich tissue [3, 4, 13]. This mechanistic coherence made the field scientifically persuasive from the outset.

Several application domains provided particularly convincing demonstrations. In liver imaging, the accumulation of SPIOs in Kupffer-cell-containing normal parenchyma created a biologically interpretable negative background against lesions lacking corresponding reticuloendothelial uptake. In lymph-node imaging, delayed USPIO uptake by normal macrophage-containing nodes offered a functional contrast mechanism distinct from conventional size criteria. In vascular disease, human carotid plaque studies demonstrated that USPIO-enhanced MRI could visualize signal changes corresponding to macrophage-rich, rupture-prone, or inflamed plaque regions [27, 29, 31, 32].

The plaque studies are especially instructive because they addressed a clinically relevant biological question that conventional angiographic anatomy does not answer directly. Kooi et al. showed that

USPIO accumulation occurred predominantly in macrophages within high-risk human carotid plaques and produced detectable post-contrast MR signal reduction [27]. Trivedi et al. further demonstrated a temporal dependence of USPIO-related signal change in human carotid atheroma, with visually evident effects beginning around 24 h after infusion and persisting across later delayed imaging time points [32]. These results did not merely show that particles can be detected; they showed that susceptibility contrast could be linked to a pathobiologically meaningful cellular process.

A second highly persuasive domain was blood-pool and vascular-function imaging. MION-like agents and ferumoxytol enabled measurements related to cerebral blood volume, microvascular physiology, angiography, and functional blood-volume imaging. Ferumoxytol became especially attractive because it combined long intravascular residence with strong MR relaxivity and practical bolus capability [6, 14, 15, 42]. This blood-pool role distinguished iron-oxide agents from delayed macrophage probes and showed that a single general class of materials could support rather different MRI strategies depending on the formulation and acquisition timing.

The inflammatory and cellular-imaging applications also generated substantial scientific value, even where translation remained incomplete. CNS lesion imaging with ferumoxtran-10, macrophage-sensitive cardiovascular MRI, and ex vivo labeling of cells for MRI tracking all demonstrated that susceptibility agents could report on biology beyond extracellular leakage [18, 26, 39, 46]. The field therefore succeeded in proving a broad principle: MRI contrast can be designed around biological trafficking and cellular uptake, not only around perfusion and nonspecific interstitial distribution.

7.2 Why Clinical Dominance Did Not Follow

The scientific strength of SPIO and USPIO imaging did not translate into broad and lasting clinical dominance. The reasons were multiple, and the cited literature supports a nuanced rather than a single-cause explanation.

A first limitation lies in the dominant image appearance itself. The most characteristic manifestation of iron-oxide accumulation is negative contrast on T_2- and T_2^*-weighted images. This signal loss can be very sensitive, but it is not intrinsically specific. Hemorrhage, calcification, tissue–air interfaces, endogenous susceptibility variation, and other causes of local field disturbance may produce similar image appearances or complicate interpretation [21, 25, 28]. Positive-contrast methods and alternative readouts were developed precisely because conventional dark-void imaging could be ambiguous, but these approaches introduced additional sequence complexity and did not establish one universally superior solution [20, 22, 25].

A second limitation is temporal logistics. Several of the biologically most interesting USPIO applications depend on delayed imaging after particle redistribution and macrophage uptake. In carotid plaque imaging, appreciable signal effects were evaluated at 24 h and later after infusion [32]. In stroke-related inflammatory imaging with ferumoxtran-10, the study protocol required repeated follow-up MRI examinations at multiple delayed time points after infusion [36]. In lymph-node imaging with ferumoxtran-10, post-contrast imaging was commonly performed about 24 h after administration, as summarized in the reviewed clinical-status article [7]. These protocols are intellectually well founded, but they are plainly less convenient than same-session contrast administration and immediate imaging.

A third problem was discontinuity in agent development and availability. The reviewed clinical-status literature notes that ferumoxtran-10 was used in some European countries but was no longer available at the

time of that report; it also states that clinical development was stopped after a multicenter prostate-cancer nodal-staging study showed a substantial false-positive rate [7]. The same review notes that development of NC100150/Clariscan was discontinued because of safety concerns [7]. Lu et al. likewise summarize that several iron-based contrast agents entered clinical trials but had discontinued development, while ferumoxytol remained commercially available primarily because of its therapeutic role as an intravenous iron preparation rather than as a formally approved MRI contrast agent [46]. Thus, the field faced not only scientific questions, but also a fragile product-development ecosystem.

Ferumoxytol partly changed the picture, but not by restoring the original SPIO/USPIO development pathway in its old form. Instead, it revived interest because it already existed as a clinically available iron-replacement drug and could be used off-label for MRI in selected settings. The literature reviewed here emphasizes its unusual combination of blood-pool behavior, macrophage uptake, and usefulness in patients for whom gadolinium-based contrast agents may raise concern [6, 46, 47]. Its renewed relevance therefore demonstrates both the scientific durability of the iron-oxide concept and the importance of commercial and regulatory continuity.

The role of competing modalities and established workflows should be treated with care. The cited literature clearly documents that gadolinium-based agents remained the dominant MRI contrast platform, while concerns about gadolinium retention later stimulated renewed interest in ferumoxytol as an alternative [46, 48]. The cited cardiovascular USPIO review also cites FDG-PET and PET/MRI approaches as parallel tools for inflammatory imaging, especially in atherosclerosis and myocardial inflammation; this observation is made here *cited after* Lu et al. rather than from those external PET studies directly [46]. What the cited literature does not establish is a single simple claim that PET, hybrid imaging, or gadolinium alone "caused" the limited adoption of SPIO/USPIO MRI. A more defensible formulation is that susceptibility-agent MRI developed in a competitive and rapidly evolving diagnostic landscape, while also carrying its own practical burdens of interpretation, scheduling, and agent availability.

7.3 Lessons from the Field

The history of SPIO and USPIO MRI demonstrates that a biologically elegant concept is not sufficient on its own. The central scientific idea was strong: use a magnetic nanoparticle whose pharmacokinetics and cellular uptake encode biologically meaningful information, then detect that information with susceptibility-sensitive MRI. The concept worked remarkably well in several settings. Yet routine clinical uptake requires that the contrast mechanism fit real imaging workflows, produce robust and readily interpretable results, and be supported by stable agent availability.

One lesson concerns workflow compatibility. Delayed imaging can be entirely justified biologically, as in macrophage or lymph-node applications, but it imposes practical costs. Patients may need to return for imaging, protocols become more complicated, and the contrast examination no longer fits neatly into the standard one-session radiology workflow. The literature on carotid plaque imaging, stroke imaging, and ferumoxtran-10 lymph-node applications makes clear that delayed imaging was often central to the method, not an incidental feature [7, 32, 36]. A promising contrast-agent biology must therefore be judged alongside the burden it places on clinical organization.

A second lesson is that biological specificity must translate into reproducible imaging specificity. Macrophage-associated uptake is attractive, but the image must still discriminate that uptake from hemorrhage, background susceptibility, passive tissue distribution, and technical artifacts. The cellular-

imaging literature teaches a related point: signal persistence does not automatically prove that the originally labeled cells remain viable or biologically active [4]. In other words, MRI may be exquisitely sensitive to iron-associated signal while still requiring careful reasoning about what that signal means.

A third lesson concerns translational resilience. Ferumoxytol illustrates why the field remains alive despite the discontinuation of several earlier agents. It is not simply a historical remnant. Because it functions as an iron therapeutic, a blood-pool MR agent, and a macrophage-sensitive susceptibility probe, it occupies a uniquely durable position at the interface of established clinical pharmacology and exploratory imaging science [6, 46, 47]. Its continued use suggests that the core ideas of SPIO/USPIO imaging remain valuable, especially where they answer questions not easily addressed by conventional extracellular contrast agents.

The translational trajectory of susceptibility contrast agents is summarized schematically in Figure 8. The figure is meant to hold both sides of the story together: on the one hand, magnetic elegance, macrophage sensitivity, and powerful blood-pool applications; on the other hand, ambiguity of negative contrast, delayed workflows, discontinued development programs, and the challenge of competing in a mature imaging ecosystem.



Figure 8: Balanced view of the translational trajectory of SPIO/USPIO MRI: scientific strengths on one side, practical and regulatory limitations on the other.

8 Safety, Tolerability, and Regulatory Context

Safety considerations for iron-oxide MRI agents cannot be treated as an afterthought, because these agents differ from conventional gadolinium chelates not only in imaging physics, but also in pharmacology, biodistribution, and regulatory history. The earlier SPIO and USPIO agents were developed for quite

different indications: ferumoxides and ferucarbotran for reticuloendothelial liver imaging, ferumoxtran-10 for macrophage-sensitive lymph-node and inflammatory imaging, NC100150/Clariscan as a blood-pool agent, and ferumoxytol primarily as an intravenous iron-replacement drug that later attracted intense off-label interest as an MRI contrast agent [6, 7, 47]. Accordingly, the safety and regulatory context is not uniform across the whole field.

For classical SPIO liver agents, the dominant clinical concern was not usually delayed inflammatory uptake but tolerability during administration and the practical value of the diagnostic examination. The review by Wang summarizes that ferumoxides and ferucarbotran became clinically used liver agents, exploiting Kupffer-cell uptake to improve lesion conspicuity, while other iron-oxide formulations had more limited market penetration or development trajectories [7]. The same review notes that NC100150/Clariscan, a blood-pool iron-oxide agent, had its development discontinued because of safety concerns [7]. Ferumoxtran-10 followed a different course: its safety profile as an imaging agent was regarded as favorable in that review, but its development for nodal staging was stopped after a multicenter prostate-cancer study reported a substantial false-positive rate, leading to unnecessary surgical interventions [7]. This distinction matters: discontinuation of an agent may arise from diagnostic-performance limitations, safety concerns, commercial factors, or combinations thereof, and these causes should not be conflated.

Ferumoxytol occupies a special position because it remained clinically available for a non-imaging indication and was subsequently explored in MRI through off-label use. Vasanawala et al. describe ferumoxytol as an ultrasmall superparamagnetic iron-oxide agent marketed for treatment of anemia in adults and increasingly adopted in MRI because of its T_1-shortening capacity, prolonged blood-pool residence, reticuloendothelial clearance, and absence of gadolinium [47]. Bashir et al. similarly emphasize its attraction as an alternative vascular and tissue contrast agent, particularly for applications in which conventional gadolinium-based contrast agents may be undesirable [6]. The point is not that ferumoxytol is automatically safer than gadolinium in every circumstance, but that it presents a materially different risk-benefit profile and became especially interesting in patient populations where gadolinium use raised specific concerns.

The most important safety issue in ferumoxytol MRI is the risk of acute infusion-related reactions. Vasanawala et al. report that postmarketing therapeutic-use data included mostly mild and transient adverse events, but also hypersensitivity reactions and hypotension [47]. In the published therapeutic-use studies summarized by those authors, the pooled aggregate rate of reported anaphylaxis was 0.03% across the cited studies, although individual study estimates varied markedly [47]. They further note that postmarket surveillance data available in March 2015 prompted the United States Food and Drug Administration to strengthen the warning for ferumoxytol, including a boxed warning after reports of serious anaphylactic reactions and fatalities in therapeutic administration [47]. These surveillance data concern therapeutic use rather than MRI-specific dosing, a distinction explicitly stated in the source and important for interpretation [47].

Practical administration therefore matters. Vasanawala et al. stress the need for careful technique, clinical monitoring, and readiness to respond to infusion reactions when ferumoxytol is used for MRI [47]. Their article reports that, across approximately 2000 patients receiving ferumoxytol for clinical MR imaging at the contributing institutions, one anaphylactoid reaction occurred in a patient with multiple prior allergies; the infusion was stopped, treatment was administered, and the patient recovered [47]. The same review cites a separate published MRI case of a grade 2 allergic reaction, again underscoring that

severe events appear uncommon in imaging practice but cannot be dismissed [47]. The proper conclusion is therefore one of disciplined caution rather than alarm or casual reassurance.

Ferumoxytol also creates MRI-specific practical issues that differ from immediate hypersensitivity. Bashir et al. point out that ferumoxytol remains intravascular at a relatively stable concentration for several hours and is then gradually cleared by macrophages and the reticuloendothelial system [6]. This prolonged persistence is diagnostically useful, but it also means that subsequent MRI examinations may be affected by residual iron-related signal changes. The same review notes measurable residual hepatic iron effects for months after administration in healthy volunteers and warns that prior ferumoxytol administration can confound later MRI interpretation [6]. Lu et al. make a related point in the cardiovascular setting, noting that manufacturer labeling indicates that MRI effects may persist for up to three months and that observational studies have described hepatic clearance over periods of several months [46]. These observations are relevant for scheduling repeat MRI and for interpreting delayed or apparently unexpected tissue signal changes.

Pregnancy and breastfeeding introduce additional uncertainty. Bashir et al. state that ferumoxytol was classified as Pregnancy Category C under the then-used FDA framework and that human data in pregnancy were unavailable, while animal data at high doses raised concern [6]. The same review notes that data on excretion into human breast milk were not available at the time discussed [6]. Since this report is restricted to the cited literature, these statements should be read as a summary of the evidence and regulatory framing given in that source, not as a current independent guideline.

The historical contrast-agent landscape is therefore uneven. Some older SPIO agents reached clinical use but faded from routine practice. Ferumoxtran-10 produced compelling macrophage-sensitive imaging results yet did not maintain a broad clinical-development path. NC100150/Clariscan was discontinued because of safety concerns. Ferumoxytol, by contrast, retained a clinically relevant pharmacological identity outside MRI and thereby remained available for off-label imaging investigation [6, 7, 47]. This explains why ferumoxytol occupies a special modern position: it is simultaneously an iron therapeutic, a blood-pool MR agent, a susceptibility-sensitive probe, and a platform for macrophage-related imaging research.

The overall lesson is that safety and translation cannot be separated from one another. Iron-oxide agents are attractive because their pharmacology creates imaging opportunities that conventional extracellular chelates do not provide. Yet that same pharmacology introduces its own responsibilities: infusion monitoring, awareness of rare but serious hypersensitivity, recognition of prolonged MRI effects, attention to off-label use, and careful distinction between agents that failed because of safety concerns and those whose limitation was diagnostic or commercial rather than toxicological.

9 Present Relevance and Future Perspectives

Susceptibility contrast agents are no longer the broadly expanding clinical platform that early enthusiasm for SPIOs and USPIOs might once have suggested. Several historically important agents disappeared from routine practice or never reached durable clinical adoption. Yet the field itself has not become obsolete. On the contrary, the cited literature shows that several of its central ideas remain highly relevant: blood-pool imaging with ferumoxytol, macrophage-sensitive imaging of inflammation, quantitative susceptibility-based assessment of particle accumulation, and the broader use of engineered magnetic nanoparticles as multifunctional imaging or theranostic systems [6, 14, 49, 50].

A first continuing line of relevance is inflammation imaging. The ability of USPIOs and ferumoxytol to accumulate in macrophage-rich tissue remains conceptually attractive in cardiovascular disease, neuroinflammation, tumor biology, and transplant-related immune processes. The application literature discussed earlier in this report shows that delayed iron-oxide imaging can reveal information different from immediate extracellular gadolinium enhancement, especially where inflammatory-cell recruitment is of interest. Bashir et al. present ferumoxytol as a particularly versatile agent because its imaging behavior spans an early vascular phase and a later macrophage-associated phase [6]. This duality remains one of the most compelling reasons why susceptibility agents continue to attract attention despite their uneven translational history.

A second continuing application is blood-pool and vascular-function MRI. Wu et al. emphasized that long-circulating USPIOs enable steady-state R_2 and R_2^* measurements for cerebral blood-volume mapping and related vascular studies, in contrast to dynamic first-pass techniques that trade spatial resolution for temporal speed [14]. Ferumoxytol extends this logic into a more clinically visible setting because its long intravascular residence provides a comparatively broad temporal window for high-resolution vascular MRI [6]. This remains relevant wherever the imaging question benefits from prolonged vascular enhancement rather than from a short conventional bolus passage alone.

A third perspective concerns quantitative imaging. Traditional negative-contrast SPIO and USPIO imaging is sensitive, but often semiquantitative and visually ambiguous. Quantitative susceptibility mapping, relaxometry, and related advanced MRI methods offer a route toward more rigorous assessment of iron-oxide accumulation. Lind et al. investigated contrast-agent concentration assessment by quantitative susceptibility mapping, while Klohs et al. used R_2^* mapping and QSM to visualize and estimate USPIO accumulation in an animal model of cerebral amyloidosis [49, 51]. The latter study explicitly notes that conventional hypointense T_2/T_2^*-weighted images do not directly quantify accumulated contrast agent, whereas susceptibility- and relaxometry-based approaches can move toward a more quantitative interpretation [51]. The future of susceptibility-agent MRI may therefore depend less on ever stronger visual darkening and more on robust quantitative readouts that can be interpreted reproducibly across studies and institutions.

The cited literature also points toward renewed interest in engineered magnetic nanoparticles beyond classical contrast enhancement. Huang et al. review the development of magnetic nanoparticles for molecular imaging, improved detection, and theranostic use, stressing that future particle design must integrate chemistry, biological targeting, relaxometric behavior, and MRI sequence capabilities [50]. Lam et al. discuss superparamagnetic iron-oxide nanoprobes for imaging and theranostic applications, while Ma et al. describe SPIO-based nanoparticles combined with indocyanine green for dual-modality imaging and photothermal therapy [52, 53]. These approaches are more experimental than established clinical susceptibility-agent MRI, but they show that the magnetic nanoparticle idea has continued to evolve rather than simply fading away. The emphasis has shifted from broad standalone diagnostic contrast agents toward multifunctional systems that combine imaging, targeting, therapy, or treatment monitoring.

A related, though therapeutically rather than diagnostically oriented, line of work was reported by van Landeghem et al., including Karl-Titus Hoffmann, who examined post-mortem glioblastoma tissue after intratumoral magnetic-nanoparticle thermotherapy and found that the particles were concentrated in necrotic tumor regions and taken up predominantly by macrophages, with only minor uptake by glioblastoma cells [54].

Multimodal nanoparticles represent a particularly visible branch of this development. Their appeal lies

in combining the deep-tissue structural and functional information of MRI with complementary optical, nuclear, or therapeutic capabilities. The present literature corpus contains examples of SPIO-containing platforms for dual-modality imaging, targeted delivery, and theranostic interventions [52, 53]. Such systems should not be presented as routine clinical successors of ferumoxides or ferumoxtran-10. They belong to a more experimental trajectory. Nevertheless, they preserve one of the fundamental ambitions of the field: to turn particle design into a way of linking contrast mechanism, biological specificity, and intervention.

A further future-facing intersection lies in advanced data analysis. The cited literature contains machine-learning work on dynamic susceptibility contrast MRI, in which perfusion parameters were estimated from source data with the aim of reducing sensitivity to noise and artifacts associated with conventional deconvolution [55]. This study did not concern SPIO or USPIO macrophage imaging specifically, and it should not be cited as direct evidence for artificial-intelligence methods in iron-oxide particle tracking. It is nevertheless methodologically relevant. Susceptibility-agent imaging often produces complex signal behavior that depends on field perturbation, compartmentalization, sequence choice, timing, and confounding background susceptibility. It is therefore reasonable to regard AI-assisted analysis, quantitative modeling, and advanced reconstruction as potentially useful companions to future susceptibility-agent MRI, while recognizing that the cited literature documents this potential only indirectly rather than establishing a mature SPIO/USPIO-specific AI methodology.

The most plausible future of susceptibility contrast agents is therefore not a simple return to the early SPIO era. Instead, the field appears to be dividing into several durable strands: ferumoxytol-based blood-pool and macrophage-sensitive imaging; quantitative MRI approaches that seek to interpret susceptibility effects more rigorously; nanoparticle systems that combine imaging with targeting or therapy; and advanced computational methods that may improve the extraction of biologically meaningful information from complex susceptibility-sensitive data. This future is more specialized than the early hopes of broad clinical replacement of gadolinium agents, but arguably also more intellectually mature. It treats iron-oxide particles not as generic darkening agents, but as physically, biologically, and computationally rich probes whose value depends on asking the right MRI question.

10 Conclusion

Susceptibility contrast agents occupy a distinctive place in the history and methodology of MRI. SPIOs, USPIOs, MION-like systems, and related iron-oxide formulations differ fundamentally from conventional extracellular gadolinium chelates in both their physical basis and their biological behavior. Their contrast effect is rooted in strong local magnetic-field perturbations generated by magnetized nanoparticle cores, leading predominantly to T_2- and T_2^*-weighted signal changes. At the same time, their diagnostic meaning depends on pharmacokinetics, reticuloendothelial uptake, vascular residence, macrophage handling, and cellular compartmentalization [3, 4, 13].

This combination of physics and biology made susceptibility agents exceptionally versatile. They supported classical liver imaging through reticuloendothelial uptake, lymph-node imaging through altered macrophage distribution, vascular inflammation imaging through plaque-associated uptake, blood-pool and perfusion methods through prolonged intravascular residence, and cellular MRI through deliberate particle loading of transplanted or migrating cells. In several of these domains, the literature contains genuinely persuasive demonstrations that iron-oxide agents can reveal information not readily available

from conventional contrast-enhanced MRI alone [6, 14, 27, 31].

Yet the clinical footprint of the field remained smaller than its scientific richness might have suggested. Negative contrast can be difficult to interpret, delayed imaging protocols complicate workflow, several historically important agents disappeared from development or routine use, and some biologically elegant applications proved demanding to standardize. The field therefore illustrates a broader truth in medical imaging: a compelling physical mechanism and a plausible biological target do not by themselves guarantee durable clinical adoption. Translation requires interpretability, reproducibility, regulatory continuity, and practical compatibility with real diagnostic workflows.

For precisely this reason, SPIOs and USPIOs remain instructive. They are not merely a historical detour in contrast-agent development, but a case study in how MRI contrast can be expanded beyond extracellular enhancement toward vascular physiology, inflammation biology, and cellular processes. Their legacy continues in ferumoxytol-based imaging, quantitative susceptibility approaches, advanced relaxometric methods, and the design of multifunctional magnetic nanoparticles [6, 49, 50]. The field may no longer promise a universal replacement for conventional MRI contrast agents, but it continues to offer a remarkably rich conceptual framework for thinking about how magnetic materials, biological distribution, and imaging methodology can be brought together in MRI.

A Detailed Magnetic and Relaxometric Theory

A.1 Single-Domain Particles and Superparamagnetism

The magnetic behavior of iron-oxide nanoparticles differs fundamentally from that of bulk magnetic materials. In sufficiently large ferrimagnetic crystals, the magnetization may be divided into multiple Weiss domains whose magnetic moments point in different directions. When the particle becomes sufficiently small, however, the energetic cost of forming domain walls exceeds the magnetostatic benefit of subdividing the crystal, and the particle adopts a single-domain state [3, 10]. In this regime, the nanoparticle behaves approximately as one coherent magnetic moment.

The orientation of this single-domain magnetic moment is constrained by magnetic anisotropy. For an idealized uniaxial particle, the anisotropy energy can be written as

$$E(\theta) = K_{\mathrm{eff}} V \sin^2 \theta, \tag{1}$$

where K_{eff} is the effective anisotropy constant, V is the magnetic-core volume, and θ is the angle between the magnetization vector and the easy axis. The energy barrier separating two equivalent easy-axis orientations is therefore of the order of $K_{\mathrm{eff}} V$ [10]. As particle size decreases, the product $K_{\mathrm{eff}} V$ decreases, making thermally activated reversal of the magnetization increasingly probable.

This thermally driven reversal of the particle magnetic moment is described by the Néel relaxation time,

$$\tau_{\mathrm{N}} = \tau_0 \exp\left(\frac{K_{\mathrm{eff}} V}{k_{\mathrm{B}} T}\right), \tag{2}$$

where τ_0 is a microscopic attempt time, k_{B} is the Boltzmann constant, and T is the absolute temperature [3, 10]. The exponential dependence on V is crucial: relatively modest changes in core size can produce very large changes in magnetic relaxation time.

Whether a particle appears superparamagnetic or magnetically blocked depends on the relation between τ_N and the timescale of the measurement. If the magnetic moment reverses many times during the observation window, the particle appears superparamagnetic, with no stable remanent magnetization. If the moment remains effectively fixed during the measurement, the particle is in a blocked state [10]. The corresponding transition is often described in terms of a *blocking temperature*, which is not a universal material constant alone, but depends on the measurement timescale and on the magnetic anisotropy barrier.

Superparamagnetism is thus characterized by a large magnetic moment in the presence of an external field and by the absence of stable remanence after the field is removed. Gossuin et al. emphasize that stable aqueous suspensions of magnetite or maghemite nanoparticles return to zero net magnetization when the applied field is switched off, even though each particle may carry a magnetic moment that is enormous compared with that of a single paramagnetic ion [3]. This combination of high field-induced magnetization and vanishing remanence is central to the usefulness of SPIOs and USPIOs as MRI contrast agents.

A.2 Brownian and Néel Contributions

Two conceptually different mechanisms can reorient the magnetic moment of a nanoparticle suspension. The first is *Néel relaxation*, in which the magnetic moment reverses within the crystal while the particle itself remains physically fixed. The second is rotational reorientation of the entire particle in the surrounding fluid. Gossuin et al. describe the return to zero macroscopic magnetization in colloidal suspensions as occurring either through Néel relaxation, when the particle is sufficiently small, or through diffusive rotation of the particle in the solvent for larger particles [3]. In the broader nanoparticle literature, this rotational contribution is commonly associated with Brownian motion.

The distinction matters because the two mechanisms respond to different physical parameters. Néel relaxation is controlled primarily by the anisotropy barrier $K_{\text{eff}}V$. It is therefore highly sensitive to core volume, composition, magnetic anisotropy, and temperature. Rotational reorientation, by contrast, depends on the mobility of the entire hydrodynamic particle in its environment and is influenced by coating, hydrodynamic size, solvent viscosity, and immobilization within cells or tissues.

This difference is especially relevant when interpreting magnetic fluctuations that contribute to longitudinal relaxivity. Caspani et al. discuss low-field T_1-related behavior of SPION systems in terms of magnetic fluctuations associated with Brownian motion or Néel relaxation [10]. These two contributions are physically distinct, but both can modulate the local magnetic field seen by surrounding water protons. Their relative importance depends on whether the particle magnetic moment is able to reorient internally, whether the whole particle can rotate, and whether the motion occurs on a timescale that efficiently couples to proton Larmor precession.

The relaxation theory becomes particularly clear when comparing smaller and larger particles. For larger magnetic crystals, the anisotropy barrier may become so high that internal moment reversal is strongly suppressed. In that case, the magnetic moment is effectively locked to the crystal anisotropy axis and Néel relaxation contributes little to the observed proton relaxation. Gossuin et al. explicitly note that, for sufficiently large magnetite particles, Néel relaxation becomes too slow to influence nuclear relaxation efficiently, while other time-modulation mechanisms, especially water diffusion around the magnetized particle, remain important [3]. Smolensky et al. make a related point in their analysis of longitudinal relaxivity, where the Néel contribution decreases as the anisotropy energy increases with crystal size [56].

A.3 Motional Averaging and Static Dephasing

The transverse relaxation effects of SPIOs and USPIOs are often discussed in terms of two limiting regimes: the *motional averaging regime* and the *static dephasing regime*. These regimes describe how water-proton diffusion interacts with the local magnetic-field gradients produced by magnetized particles.

In the motional averaging regime, particles are sufficiently small, or field perturbations sufficiently moderate, that water protons diffuse through the spatially varying field rapidly compared with the frequency offsets caused by the particles. Each proton therefore samples many local field values during the relevant observation time, and the susceptibility perturbation is partially averaged by diffusion. In this regime, the transverse relaxation rate increases with particle size, and the distinction between R_2 and R_2^* is relatively modest [11, 50].

In the static dephasing regime, the local field perturbation becomes stronger and proton diffusion is no longer fast enough to average it efficiently. Protons experience quasi-static frequency offsets over the timescale of signal evolution, leading to pronounced irreversible dephasing on gradient-echo readouts. In this limit, R_2^* becomes more strongly affected than R_2, and further enlargement of the magnetic particle does not necessarily produce a proportional gain in spin-echo T_2 relaxivity [11, 50]. The resulting saturation of relaxivity with particle size is a central prediction of static-dephasing theory.

The conceptual distinction between the two regimes is especially useful for understanding why particle enlargement improves T_2 contrast only up to a point. Small single-core nanoparticles often operate in, or near, the motional averaging regime, where increasing size and magnetic moment increase transverse relaxivity. Larger cores, dense clusters, and strongly magnetized aggregates may approach the static dephasing regime, where the susceptibility-induced field gradients are already strong and additional size increase produces diminishing returns [11, 50].

Classical work on magnetized spheres established the importance of diffusion through local magnetic-field gradients for transverse relaxation, and later scaling analyses generalized these ideas to modern magnetic nanoparticles and clusters [9, 11]. For the purposes of MRI contrast-agent design, the practical message is that the observed T_2 and T_2^* effects are not determined by magnetization alone, but by the interplay between field perturbation strength, particle dimensions, spatial organization, and proton diffusion.

A.4 Scaling of Relaxivity

Relaxivity is the operational measure of how efficiently a contrast agent changes proton relaxation rates per concentration unit. For iron-oxide nanoparticles, the transverse relaxivity r_2 is particularly important, but the longitudinal relaxivity r_1 also becomes relevant for very small particles, low-field conditions, and selected positive-contrast applications. The cited literature makes clear that relaxivity is controlled by several interdependent structural and magnetic variables rather than by a single particle-size number.

Particle size. Particle size influences both magnetization and the spatial extent of the local field perturbation. In their systematic study of MIONs, Smolensky et al. showed that magnetic properties and relaxivities depend strongly on particle size and shape. For faceted magnetite nanoparticles, both r_1 and r_2 increased with size up to the largest particles investigated, while saturation magnetization increased with size before approaching a plateau [56]. These findings support the general principle that increasing the magnetic core can improve relaxivity, but they also show that the relationship is material-

and morphology-dependent rather than universally linear.

Magnetic moment and saturation magnetization. The local magnetic-field disturbance generated by a particle scales with its magnetic moment. Consequently, particles with higher saturation magnetization are generally expected to produce stronger susceptibility effects. Smolensky et al. emphasize that composition, morphology, and crystallinity influence saturation magnetization and thereby relaxivity [56]. Vuong et al. similarly formulated a transverse-relaxivity scaling framework in which particle magnetization is one of the central predictive parameters [11].

Aggregation and geometry. Aggregation changes the effective magnetic architecture seen by diffusing water protons. A cluster of small cores may produce a very different susceptibility field from an isolated single crystal of equal total iron content. Vuong et al. proposed that, for particles assembled from several magnetic cores, transverse relaxation efficiency can be predicted using not only a characteristic size and magnetization, but also the intra-aggregate volume fraction occupied by magnetic material [11]. This formulation accommodates dense clusters, fractal aggregates, core–shell constructs, and vesicular architectures within one common scaling picture.

Smolensky et al. likewise identify mutual anisotropy induced by dipolar coupling between nearby crystals as an important contributor to relaxometric behavior in aggregated structures [56]. Thus, aggregation is not merely an unwanted colloidal complication; it can fundamentally alter magnetic coupling, field geometry, and relaxivity.

Field-strength dependence. The influence of field strength differs for longitudinal and transverse relaxivity. Smolensky et al. report that transverse relaxivity in their investigated USPIO systems showed little dependence on field strength over a broad measured frequency range once magnetization was effectively saturated, whereas longitudinal relaxivity displayed a much more complex dependence on field and particle size [56]. Gossuin et al. also describe the magnetic moment as increasing with field according to a Langevin-type behavior before approaching saturation [3]. These findings explain why field-strength dependence cannot be summarized by a single monotonic rule valid for both r_1 and r_2.

At a conceptual level, T_2-dominated susceptibility contrast benefits from strong local field perturbations and often remains robust at conventional clinical field strengths, whereas T_1-related behavior is more sensitive to the matching of magnetic fluctuations and proton Larmor frequency. This helps explain why SPIOs and USPIOs are usually discussed as predominantly T_2/T_2^* agents, even though specific nanoparticle designs and field regimes can yield useful T_1-weighted effects [3, 10, 56].

Figure 9 summarizes these theoretical ideas in graphical form. It connects the single-domain origin of superparamagnetism with Néel relaxation, rotational reorientation, diffusion-mediated motional averaging, static dephasing, and the main parameters that govern relaxivity scaling.



Figure 9: Conceptual summary of theoretical regimes relevant to SPIO/USPIO contrast generation, including superparamagnetism, local field perturbation, diffusion-driven averaging, and static dephasing.

B Compact Agent Catalogue

Table 1: Compact catalogue of major iron-oxide susceptibility contrast agents: formulation and approximate size. Sizes refer to approximate hydrodynamic particle diameters where reported in the cited literature.

Agent	Class	Coating	Approx. size
Ferumoxides	SPIO	Dextran T10	ca. 120–180 nm
Ferucarbotran	SPIO	Carboxydextran	ca. 60–62 nm
Ferumoxtran-10	USPIO	Dextran T10/T1	ca. 15–30 nm; some reports describe 20–50 nm
Ferumoxytol	USPIO	Polyglucose sorbitol carboxymethyl ether	ca. 17–31 nm; often summarized as about 30 nm
MION	USPIO-like monocrystalline system	Typically dextran-coated in the classical AMI-227/MION context	Magnetic core ca. 4–6 nm; overall formulation belongs to the small USPIO range
Other examples: SHU 555 C, NC100150/Clariscan, VSOP-C184	USPIO / VSPIO	Carboxydextran; PEGylated starch; citrate, respectively	ca. 7–21 nm, agent-dependent

Table 2: Compact catalogue of major iron-oxide susceptibility contrast agents: principal imaging roles and translational status.

Agent	Main role	Status
Ferumoxides	Classical reticuloendothelial liver and spleen imaging; lesion conspicuity through strong uptake in normal macrophage-rich parenchyma	Historically clinically approved liver MRI agent, marketed as Feridex/Endorem [5, 7]
Ferucarbotran	Liver MRI and reticuloendothelial imaging; bolus-compatible SPIO formulation	Historically clinically approved liver MRI agent, marketed as Resovist [5, 7]
Ferumoxtran-10	Delayed macrophage-sensitive imaging, especially lymph-node imaging, inflammatory lesions, and CNS/tumor applications	Investigational imaging agent; clinical development was stopped after disappointing nodal-staging performance despite substantial scientific interest [5, 7]
Ferumoxytol	Blood-pool MRI, MRA, perfusion and blood-volume imaging; delayed enhancement related to vascular leakiness and inflammatory-cell involvement	Approved as an intravenous iron-replacement drug; widely studied and used off-label as an MRI contrast agent [6, 13]
MION	Experimental blood-pool agent for steady-state cerebral blood-volume mapping, vascular physiology, and perfusion-related research	Primarily experimental / preclinical research platform rather than a routine clinical contrast agent [14]
Other examples: SHU 555 C, NC100150/Clariscan, VSOP-C184	Blood-pool imaging, angiography, vascular or targeted nanoparticle research, depending on formulation	Mixed translational status: investigational, discontinued, or limited to specialized research settings [5, 7]

Bibliography

[1] Yu-Dong Xiao, Ramchandra Paudel, Jun Liu, Cong Ma, Zi-Shu Zhang, and Shun-Ke Zhou. Mri contrast agents: Classification and application (review). *International Journal of Molecular Medicine*, 38(5):1319–1326, 2016. doi: 10.3892/ijmm.2016.2744. URL https://doi.org/10.3892/ijmm.2016.2744.

[2] Jessica Wahsner, Eric M. Gale, Aurora Rodríguez-Rodríguez, and Peter Caravan. Chemistry of mri contrast agents: Current challenges and new frontiers. *Chemical Reviews*, 119(2):957–1057, 2019. doi: 10.1021/acs.chemrev.8b00363. URL https://doi.org/10.1021/acs.chemrev.8b00363.

[3] Yves Gossuin, Pierre Gillis, Aline Hocq, Quoc L Vuong, and Alain Roch. Magnetic resonance relaxation properties of superparamagnetic particles. *WIREs Nanomedicine and Nanobiotechnology*, 1(3):299–310, 2009. doi: 10.1002/wnan.36. URL https://doi.org/10.1002/wnan.36.

[4] Jeff W. M. Bulte and Dara L. Kraitchman. Iron oxide mr contrast agents for molecular and cellular imaging. *NMR in Biomedicine*, 17(7):484–499, 2004. doi: 10.1002/nbm.924. URL https://doi.org/10.1002/nbm.924.

[5] Jason S Weinstein, Csanad G Varallyay, Edit Dosa, Seymur Gahramanov, Bronwyn Hamilton, William D Rooney, Leslie L Muldoon, and Edward A Neuwelt. Superparamagnetic iron oxide nanoparticles: Diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. *Journal of Cerebral Blood Flow & Metabolism*, 30(1):15–35, 2010. doi: 10.1038/jcbfm.2009.192. URL https://doi.org/10.1038/jcbfm.2009.192.

[6] Mustafa R. Bashir, Lubna Bhatti, Daniele Marin, and Rendon C. Nelson. Emerging applications for ferumoxytol as a contrast agent in mri. *Journal of Magnetic Resonance Imaging*, 41(4):884–898, 2015. doi: 10.1002/jmri.24691. URL https://doi.org/10.1002/jmri.24691.

[7] Yi-Xiang J. Wang. Superparamagnetic iron oxide based mri contrast agents: Current status of clinical application. *Quantitative Imaging in Medicine and Surgery*, 1(1):35–40, 2011. doi: 10.3978/j.issn.2223-4292.2011.08.03.

[8] Pádraig Cantillon-Murphy, Lawrence L. Wald, Markus Zahn, and Elfar Adalsteinsson. Measuring spio and gd contrast agent magnetization using 3 t mri. *NMR in Biomedicine*, 22(8):891–897, 2009. doi: 10.1002/nbm.1412. URL https://doi.org/10.1002/nbm.1412.

[9] Pierre Gillis and Seymour H. Koenig. Transverse relaxation of solvent protons induced by magnetized spheres: Application to ferritin, erythrocytes, and magnetite. *Magnetic Resonance in Medicine*, 5(4):323–345, 1987. doi: 10.1002/mrm.1910050404. URL https://doi.org/10.1002/mrm.1910050404.

[10] Sofia Caspani, Ricardo Magalhães, João Pedro Araújo, and Célia Tavares Sousa. Magnetic nanomaterials as contrast agents for mri. *Materials*, 13(11):2586, 2020. doi: 10.3390/ma13112586. URL https://doi.org/10.3390/ma13112586.

[11] Quoc L. Vuong, Jean-François Berret, Jérôme Fresnais, Yves Gossuin, and Olivier Sandre. A universal scaling law to predict the efficiency of magnetic nanoparticles as mri t2-contrast agents. *Advanced Healthcare Materials*, 1(4):502–512, 2012. doi: 10.1002/adhm.201200078. URL https://doi.org/10.1002/adhm.201200078.

[12] Gerhard H. Simon, Jan Bauer, Olaf Saborovski, Yanjun Fu, Claire Corot, Michael F. Wendland, and Heike E. Daldrup-Link. T1 and t2 relaxivity of intracellular and extracellular uspio at 1.5t and 3t clinical mr scanning. *European Radiology*, 16(3):738–745, 2006. doi: 10.1007/s00330-005-0031-2. URL https://doi.org/10.1007/s00330-005-0031-2.

[13] Edward A. Neuwelt, Bronwyn E. Hamilton, Csanad G. Varallyay, William R. Rooney, Robert D. Edelman, Paula M. Jacobs, and Suzanne G. Watnick. Ultrasmall superparamagnetic iron oxides (uspios): a future alternative magnetic resonance (mr) contrast agent for patients at risk for nephrogenic systemic fibrosis (nsf)? *Kidney International*, 75(5):465–474, 2009. doi: 10.1038/ki.2008.496. URL https://doi.org/10.1038/ki.2008.496.

[14] Ed X. Wu, Haiying Tang, and Jens H. Jensen. Applications of ultrasmall superparamagnetic iron oxide contrast agents in the mr study of animal models. *NMR in Biomedicine*, 17(7):478–483, 2004. doi: 10.1002/nbm.923. URL https://doi.org/10.1002/nbm.923.

[15] Wei Li, Sean Tutton, Anthony T. Vu, Linda Pierchala, Belinda S.Y. Li, Jerome M. Lewis, Pottumarthi V. Prasad, and Robert R. Edelman. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (uspio)-based blood pool agent. *Journal of Magnetic Resonance Imaging*, 21(1):46–52, 2005. doi: 10.1002/jmri.20235. URL https://doi.org/10.1002/jmri.20235.

[16] Ashley M. Stokes, Natenael Semmineh, and C. Chad Quarles. Validation of a t₁and t2* leakage correction method based on multiecho dynamic susceptibility contrast mri using mion as a reference standard. *Magnetic Resonance in Medicine*, 76(2):613–625, 2016. doi: 10.1002/mrm.25906. URL https://doi.org/10.1002/mrm.25906.

[17] Seymur Gahramanov, Leslie L. Muldoon, Xin Li, and Edward A. Neuwelt. Improved perfusion mr imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. *Radiology*, 261(3):796–804, 2011. doi: 10.1148/radiol.11103503. URL https://doi.org/10.1148/radiol.11103503.

[18] Raoul D Oude Engberink, Erwin L A Blezer, Erik I Hoff, Susanne M A van der Pol, Annette van der Toorn, Rick M Dijkhuizen, and Helga E de Vries. Mri of monocyte infiltration in an animal model of neuroinflammation using spio-labeled monocytes or free uspio. *Journal of Cerebral Blood Flow & Metabolism*, 28(4):841–851, 2008. doi: 10.1038/sj.jcbfm.9600580. URL https://doi.org/10.1038/sj.jcbfm.9600580.

[19] Juan D. López-Castro, Adrian V. Maraloiu, J. J. Delgado, J. J. Calvino, M.-G. Blanchin, Natividad Gálvez, and José M. Domínguez-Vera. From synthetic to natural nanoparticles: monitoring the biodegradation of spio (p904) into ferritin by electron microscopy. *Nanoscale*, 3(11):4597, 2011. doi: 10.1039/c1nr10980d. URL https://doi.org/10.1039/c1nr10980d.

[20] Hannes Dahnke, Wei Liu, Daniel Herzka, Joseph A. Frank, and Tobias Schaeffter. Susceptibility gradient mapping (sgm): A new postprocessing method for positive contrast generation applied to superparamagnetic iron oxide particle (spio)-labeled cells. *Magnetic Resonance in Medicine*, 60(3): 595–603, 2008. doi: 10.1002/mrm.21478. URL https://doi.org/10.1002/mrm.21478.

[21] Rong Zhou, Djaudat Idiyatullin, Steen Moeller, Curt Corum, Hualei Zhang, Hui Qiao, Jia Zhong, and Michael Garwood. Swift detection of spio-labeled stem cells grafted in the myocardium. *Magnetic Resonance in Medicine*, 63(5):1154–1161, 2010. doi: 10.1002/mrm.22378. URL https://doi.org/10.1002/mrm.22378.

[22] Chenghong Lin, Shuhui Cai, and Jianghua Feng. Positive contrast imaging of spio nanoparticles. *Journal of Nanomaterials*, 2012(1), 2012. doi: 10.1155/2012/734842. URL https://doi.org/10.1155/2012/734842.

[23] Catherine Chambon, Olivier Clement, Alain Le Blanche, Elisabeth Schouman-Claeys, and Guy Frija. Superparamagnetic iron oxides as positive mr contrast agents: In vitro and in vivo evidence. *Magnetic Resonance Imaging*, 11(4):509–519, 1993. doi: 10.1016/0730-725x(93)90470-x. URL https://doi.org/10.1016/0730-725x(93)90470-x.

[24] Priti Balchandani, Mayumi Yamada, John Pauly, Phillip Yang, and Daniel Spielman. Self-refocused spatial-spectral pulse for positive contrast imaging of cells labeled with spio nanoparticles. *Magnetic Resonance in Medicine*, 62(1):183–192, 2009. doi: 10.1002/mrm.21973. URL https://doi.org/10.1002/mrm.21973.

[25] Wei Liu, Hannes Dahnke, E. Kay Jordan, Tobias Schaeffter, and Joseph A. Frank. In vivo mri using positive-contrast techniques in detection of cells labeled with superparamagnetic iron oxide nanoparticles. *NMR in Biomedicine*, 21(3):242–250, 2008. doi: 10.1002/nbm.1187. URL https://doi.org/10.1002/nbm.1187.

[26] Sándor P. Manninger, Leslie L. Muldoon, Gary Nesbit, Tulio Murillo, Paula M. Jacobs, and Edward A. Neuwelt. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in cns inflammatory lesions. *AJNR American Journal of Neuroradiology*, 26(9):2290–2300, 2005.

[27] M.E. Kooi, V.C. Cappendijk, K.B.J.M. Cleutjens, A.G.H. Kessels, P.J.E.H.M. Kitslaar, M. Borgers, P.M. Frederik, M.J.A.P. Daemen, and J.M.A. van Engelshoven. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. *Circulation*, 107(19):2453–2458, 2003. doi: 10.1161/01.cir.0000068315.98705.cc. URL https://doi.org/10.1161/01.cir.0000068315.98705.cc.

[28] Vivek Sehgal, Zachary Delproposto, Djamel Haddar, E. Mark Haacke, Andrew E. Sloan, Lucia J. Zamorano, Geoffery Barger, Jiani Hu, Yingbiao Xu, Karthik Praveen Prabhakaran, Ilaya R. Elangovan, Jaladhar Neelavalli, and Jürgen R. Reichenbach. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. *Journal of Magnetic Resonance Imaging*, 24(1):41–51, 2006. doi: 10.1002/jmri.20598. URL https://doi.org/10.1002/jmri.20598.

[29] Thomas J. Vogl, Wolfram Schwarz, Stefan Blume, Michael Pietsch, Kohkan Shamsi, Martina Franz, Hartmut Lobeck, Thomas Balzer, Kelly del Tredici, Peter Neuhaus, Roland Felix, and Renate M. Hammerstingl. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and spio (resovist)-enhanced mr imaging with biphasic ctap and intraoperative us. *European Radiology*, 13(2):262–272, 2003. doi: 10.1007/s00330-002-1677-7. URL https://doi.org/10.1007/s00330-002-1677-7.

[30] Luigi Grazioli, Giovanni Morana, Miles A. Kirchin, Paolo Caccia, Laura Romanini, Maria P. Bondioni, Carlo Procacci, and Antonio Chiesa. Mri of focal nodular hyperplasia (fnh) with gadobenate dimeglumine (gd-bopta) and spio (ferumoxides): An intra-individual comparison. *Journal of Magnetic Resonance Imaging*, 17(5):593–602, 2003. doi: 10.1002/jmri.10289. URL https://doi.org/10.1002/jmri.10289.

[31] Marie-France Bellin, Catherine Beigelman, and Sophie Precetti-Morel. Iron oxide-enhanced mr lymphography: initial experience. *European Journal of Radiology*, 34(3):257–264, 2000. doi: 10.1016/s0720-048x(00)00204-7. URL https://doi.org/10.1016/s0720-048x(00)00204-7.

[32] Rikin A. Trivedi, Chinthake Mallawarachi, Jean-Marie U-King-Im, Martin J. Graves, Jo Horsley, Martin J. Goddard, Andrew Brown, Liqun Wang, Peter J. Kirkpatrick, John Brown, and Jonathan H. Gillard. Identifying inflamed carotid plaques using in vivo uspio-enhanced mr imaging to label plaque macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 26(7):1601–1606, 2006. doi: 10.1161/01.atv.0000222920.59760.df. URL https://doi.org/10.1161/01.atv.0000222920.59760.df.

[33] Tjun Tang, Simon P.S. Howarth, Sam R. Miller, Rikin Trivedi, Martin J. Graves, Jean U. King-Im, Zhi Y. Li, Andrew P. Brown, Peter J. Kirkpatrick, Michael E. Gaunt, and Jonathan H. Gillard. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide–enhanced mri. *Stroke*, 37(9):2266–2270, 2006. doi: 10.1161/01.str.0000236063.47539.99. URL https://doi.org/10.1161/01.str.0000236063.47539.99.

[34] Loek P. Smits, Feiko Tiessens, Kang He Zheng, Erik S. Stroes, Aart J. Nederveen, and Bram F. Coolen. Evaluation of ultrasmall superparamagnetic iron-oxide (uspio) enhanced mri with ferumoxytol to quantify arterial wall inflammation. *Atherosclerosis*, 263:211–218, 2017. doi: 10.1016/j.atherosclerosis.2017.06.020. URL https://doi.org/10.1016/j.atherosclerosis.2017.06.020.

[35] Andreas Saleh, Michael Schroeter, Adrian Ringelstein, Hans-Peter Hartung, Mario Siebler, Ulrich Mödder, and Sebastian Jander. Iron oxide particle-enhanced mri suggests variability of brain inflammation at early stages after ischemic stroke. *Stroke*, 38(10):2733–2737, 2007. doi: 10.1161/strokeaha.107.481788. URL https://doi.org/10.1161/strokeaha.107.481788.

[36] Norbert Nighoghossian, Marlène Wiart, Serkan Cakmak, Yves Berthezène, Laurent Derex, Tae-Hee Cho, Chantal Nemoz, François Chapuis, Guy-Louis Tisserand, Jean-Baptiste Pialat, Paul Trouillas, Jean-Claude Froment, and Marc Hermier. Inflammatory response after ischemic stroke. *Stroke*, 38(2):303–307, 2007. doi: 10.1161/01.str.0000254548.30258.f2. URL https://doi.org/10.1161/01.str.0000254548.30258.f2.

[37] Tulio P Murillo, Chloe Sandquist, Paula M Jacobs, Gary Nesbit, Sandor Manninger, and Edward A Neuwelt. Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. *Therapy*, 2(6):871–882, 2005. doi: 10.1586/14750708.2.6.871. URL https://doi.org/10.1586/14750708.2.6.871.

[38] Heike E. Daldrup-Link, Daniel Golovko, Brian Ruffell, David G. DeNardo, Rosalinda Castaneda, Celina Ansari, Jianghong Rao, Grigory A. Tikhomirov, Michael F. Wendland, Claire Corot, and Lisa M. Coussens. Mri of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. *Clinical Cancer Research*, 17(17):5695–5704, 2011. doi: 10.1158/1078-0432.ccr-10-3420. URL https://doi.org/10.1158/1078-0432.ccr-10-3420.

[39] Ali S. Arbab, Gene T. Yocum, Heather Kalish, Elaine K. Jordan, Stasia A. Anderson, Aarif Y. Khakoo, Elizabeth J. Read, and Joseph A. Frank. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular mri. *Blood*, 104(4):1217–1223, 2004. doi: 10.1182/blood-2004-02-0655. URL https://doi.org/10.1182/blood-2004-02-0655.

[40] Alexander Y. Sheu, Zhuoli Zhang, Reed A. Omary, and Andrew C. Larson. Mri-monitored transcatheter intra-arterial delivery of spio-labeled natural killer cells to hepatocellular carcinoma. *Investigative Radiology*, 48(6):492–499, 2013. doi: 10.1097/rli.0b013e31827994e5. URL https://doi.org/10.1097/rli.0b013e31827994e5.

[41] Richard Schäfer, Miriam Ayturan, Rüdiger Bantleon, Rainer Kehlbach, Joerg Pintaske, Sabine Conrad, Hartwig Wolburg, Jakub Wiskirchen, and Robert Weissert. The use of clinically approved small particles of iron oxide (spio) for labeling of mesenchymal stem cells aggravates clinical symptoms in experimental autoimmune encephalomyelitis and influences their in vivo distribution. *Cell Transplantation*, 17(8):923–941, 2008. doi: 10.3727/096368908786576480. URL https://doi.org/10.3727/096368908786576480.

[42] Deqiang Qiu, Greg Zaharchuk, Thomas Christen, Wendy W. Ni, and Michael E. Moseley. Contrast-enhanced functional blood volume imaging (ce-fbvi): Enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol. *NeuroImage*, 62(3):1726–1731, 2012. doi: 10.1016/j.neuroimage.2012.05.010. URL https://doi.org/10.1016/j.neuroimage.2012.05.010.

[43] Csanad G. Varallyay, Eric Nesbit, Andrea Horvath, Peter Varallyay, Rongwei Fu, Seymur Gahramanov, Leslie L. Muldoon, Xin Li, William D. Rooney, and Edward A. Neuwelt. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion mri: Comparison to standard of care. *Journal of Magnetic Resonance Imaging*, 48(2):441–448, 2018. doi: 10.1002/jmri.25943. URL https://doi.org/10.1002/jmri.25943.

[44] Shirjel R. Alam, Anoop S.V. Shah, Jennifer Richards, Ninian N. Lang, Gareth Barnes, Nikhil Joshi, Tom MacGillivray, Graham McKillop, Saeed Mirsadraee, John Payne, Keith A.A. Fox, Peter Henriksen, David E. Newby, and Scott I.K. Semple. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction. *Circulation: Cardiovascular Imaging*, 5(5):559–565, 2012. doi: 10.1161/circimaging.112.974907. URL https://doi.org/10.1161/circimaging.112.974907.

[45] Jakub Lagan, Josephine H. Naish, Kara Simpson, Min Zi, Elizabeth J. Cartwright, Phil Foden, Julie Morris, David Clark, Lindsay Birchall, Jessica Caldwell, Andrew Trafford, Christien Fortune, Michael Cullen, Nazia Chaudhuri, James Fildes, Jaydeep Sarma, Erik B. Schelbert, Matthias Schmitt, Karen Piper Hanley, and Christopher A. Miller. Substrate for the myocardial inflammation–heart failure hypothesis identified using novel uspio methodology. *JACC: Cardiovascular Imaging*, 14(2): 365–376, 2021. doi: 10.1016/j.jcmg.2020.02.001. URL https://doi.org/10.1016/j.jcmg.2020.02.001.

[46] Yi Lu, Jenny Huang, Natalia V. Neverova, and Kim-Lien Nguyen. Uspios as targeted contrast agents in cardiovascular magnetic resonance imaging. *Current Cardiovascular Imaging Reports*, 14(2), 2021. doi: 10.1007/s12410-021-09552-8. URL https://doi.org/10.1007/s12410-021-09552-8.

[47] Shreyas S. Vasanawala, Kim-Lien Nguyen, Michael D. Hope, Mellena D. Bridges, Thomas A. Hope, Scott B. Reeder, and Mustafa R. Bashir. Safety and technique of ferumoxytol administration for mri. *Magnetic Resonance in Medicine*, 75(5):2107–2111, 2016. doi: 10.1002/mrm.26151. URL https://doi.org/10.1002/mrm.26151.

[48] Gesine Knobloch, Timothy Colgan, Curtis N. Wiens, Xiaoke Wang, Tilman Schubert, Diego Hernando, Samir D. Sharma, and Scott B. Reeder. Relaxivity of ferumoxytol at 1.5 t and 3.0 t. *Investigative Radiology*, 53(5):257–263, 2018. doi: 10.1097/rli.0000000000000434. URL https://doi.org/10.1097/rli.0000000000000434.

[49] Emelie Lind, Linda Knutsson, Robin Kämpe, Freddy Ståhlberg, and Ronnie Wirestam. Assessment of mri contrast agent concentration by quantitative susceptibility mapping (qsm): application to estimation of cerebral blood volume during steady state. *Magnetic Resonance Materials in Physics, Biology and Medicine*, 30(6):555–566, 2017. doi: 10.1007/s10334-017-0637-9. URL https://doi.org/10.1007/s10334-017-0637-9.

[50] Jing Huang, Xiaodong Zhong, Liya Wang, Lily Yang, and Hui Mao. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. *Theranostics*, 2(1): 86–102, 2012. doi: 10.7150/thno.4006. URL https://doi.org/10.7150/thno.4006.

[51] Jan Klohs, Andreas Deistung, Giovanna D Ielacqua, Aline Seuwen, Diana Kindler, Ferdinand Schweser, Markus Vaas, Anja Kipar, Jürgen R Reichenbach, and Markus Rudin. Quantitative assessment of microvasculopathy in arcaβ mice with uspio-enhanced gradient echo mri. *Journal of Cerebral Blood Flow & Metabolism*, 36(9):1614–1624, 2016. doi: 10.1177/0271678x15621500. URL https://doi.org/10.1177/0271678x15621500.

[52] Tina Lam, Philippe Pouliot, Pramod K. Avti, Frédéric Lesage, and Ashok K. Kakkar. Superparamagnetic iron oxide based nanoprobes for imaging and theranostics. *Advances in Colloid and Interface Science*, 199-200:95–113, 2013. doi: 10.1016/j.cis.2013.06.007. URL https://doi.org/10.1016/j.cis.2013.06.007.

[53] Yan Ma, Sheng Tong, Gang Bao, Chuang Gao, and Zhifei Dai. Indocyanine green loaded spio nanoparticles with phospholipid-peg coating for dual-modal imaging and photothermal therapy. *Biomaterials*, 34(31):7706–7714, 2013. doi: 10.1016/j.biomaterials.2013.07.007. URL https://doi.org/10.1016/j.biomaterials.2013.07.007.

[54] Frank K. H. van Landeghem, K. Maier-Hauff, A. Jordan, Karl-Titus Hoffmann, U. Gneveckow, R. Scholz, B. Thiesen, W. Brück, and A. von Deimling. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. *Biomaterials*, 30(1):52–57, 2009. doi: 10.1016/j.biomaterials.2008.09.044.

[55] Richard McKinley, Fan Hung, Roland Wiest, David S. Liebeskind, and Fabien Scalzo. A machine learning approach to perfusion imaging with dynamic susceptibility contrast mr. *Frontiers in Neurology*, 9, 2018. doi: 10.3389/fneur.2018.00717. URL https://doi.org/10.3389/fneur.2018.00717.

[56] Eric D. Smolensky, Hee-Yun E. Park, Yue Zhou, Gabriele A. Rolla, Małgorzata Marjańska, Mauro Botta, and Valérie C. Pierre. Scaling laws at the nanosize: the effect of particle size and shape on the magnetism and relaxivity of iron oxide nanoparticle contrast agents. *Journal of Materials Chemistry B*, 1(22):2818, 2013. doi: 10.1039/c3tb00369h. URL https://doi.org/10.1039/c3tb00369h.